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Abstract 
 
Decades of overuse of antibiotics has led to the emergence of resistant infections 
across the globe. Healthcare professionals are running out of viable options, as clinical 
isolates have begun resisting treatment to even last resort therapies. The emergence of 
these ‘superbugs’, coupled with the lack of new drugs in the discovery pipeline, has led 
to the possibility of a ‘post-antibiotic’ era. 
With the primary driving force for resistance development being the overuse of 
antibiotics, technologies are being sought to limit their injudicious application within the 
clinical and agricultural sectors. An attractive contender in the fight against microbial 
resistance are antimicrobial peptides (AMPs). AMPs are small peptides that are produced 
natively from organisms across all domains of life as a first line of defense against 
microbial challenge. However, despite decades of research on their therapeutic potential, 
AMPs have widely failed in translational success due to delivery and synthesis 
challenges.  
Many AMPs are unable to survive passage to the gastrointestinal (GI) tract, the 
residence of many bacterial pathogens, limiting their utility to topical applications. In this 
work, we propose engineering probiotic bacteria as AMP-delivery vehicles to overcome 
their inherent transport barriers and localize their production at the site of infection. We 
focus on modifying the probiotic, E. coli Nissle 1917 (EcN), which has shown promise in 
both human and animal health.  
This work takes a synthetic biology approach to iteratively improve and redesign 
AMP biosynthetic gene clusters. Through strong collaborations with the Veterans’ 
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Affairs Medical Center and Department of Veterinary Sciences, the work within takes a 
highly translational approach incorporating professional veterinary and clinical oversight 
at the design stages to develop systems with meaningful downstream applications. 
We describe our development of an engineered EcN derivative, EcN(J25), that 
has antagonistic activity against foodborne Salmonella. With EcN(J25), we demonstrated 
the first in vivo success of AMP-producing probiotics. EcN(J25) was capable of reducing 
Salmonella carriage in poultry by 97% after a two-week period with no detectable impact 
on the native microbiome. This proof-of-concept opens an alternative method to reduce 
pathogen counts in livestock without incorporating medically important antibiotics in the 
feed supply.  
We then developed an alternative EcN derivative, EcN(C7), which targets the 
rising multi-drug resistant E. coli strain, sequence Type ST131. The goal was to develop 
an engineered probiotic that could be used as a decolonization measure for ST131 in the 
clinic. We further explored mechanisms of resistance of ST131 to aid in the development 
of future combination therapies.  
We also describe our development of two new synthetic biology tools, ProTeOn+ 
and pMPES. ProTeOn+ is a synthetic-hybrid promoter that enables robust protein 
expression without exogenous induction. ProTeOn+ has demonstrated functional utility 
in many of the described engineered AMP networks. pMPES serves as a modular peptide 
expression system that allows heterologous secretion of a variety of AMPs from EcN.  
This work take a synthetic biology perspective to describe many of the challenges 
and potential of engineered probiotics, laying a foundation for future work in this field. 
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Chapter 1 Introduction 
1.1 The Rise of Antibiotic Resistant Bacteria 
The discovery of antibiotics in the 1920s revolutionized modern medicine, 
providing cures for some of the most widespread diseases of the time. Between 1940 and 
1960, the ‘Golden Age’ of antibiotics took place, where many hallmark drugs were 
developed such as the penicillins, cephalosporins, and aminoglycosides. Antibiotics have 
since saved millions of lives each year and have contributed to increasing the average life 
expectancy in the United States from 47yrs in 1900 to approximately 80yrs today1. 
However, concern is rising as bacteria are developing resistance mechanisms to 
traditional antibiotics. Resistant infections lead to prolonged illnesses, increased medical 
costs, and more treatment failures. Each year in the U.S. alone, two million people are 
infected with antibiotic resistant bacteria which result in 23,000 fatalities2. Estimates 
predict that, in the absence of a solution, resistant infections could surpass cancer in total 
annual deaths by 20503. 
This problem is coupled with the fact that antibiotic discovery has largely 
declined1. Only one new antibiotic class has been discovered in over 30 years4. 
Analogous of existing drugs have mitigated the impact of this lack of discovery but even 
their rate of development can no longer adequately compete with the rate of resistance 
emergence5. A major contributor to the paucity of antibiotics is that pharmaceutical 
companies have shifted away from antibiotic research for reasons including increased 
regulatory expenses, research challenges, and low returns on investment1.  
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The threat of antimicrobial resistance has received global attention, with the U.S. 
implementing the National Action Plan for Combating Antibiotic-Resistant Bacteria in 
2015. This plan outlines goals to reduce microbial infections in half by 2020. This plan 
focuses on promoting the research of new therapeutic and diagnostic methods, 
strengthening surveillance efforts, and fostering international collaboration to combat 
resistance emergence. With the overuse of antibiotics being a root cause of resistance 
development, this plan also emphasizes reducing the unnecessary application of 
antibiotics throughout healthcare and agriculture1. 
Epidemiological studies have found a direct relationship between antibiotic use 
and the emergence and dissemination of resistant strains. When antibiotics are applied to 
a microbial population, they apply a selective pressure which breeds resistance 
development by eradicating the drug-sensitive population and allowing the resistant 
subset to thrive and pass on their resistance markers to succeeding and/or neighboring 
microbes. Resistance can be acquired through spontaneous mutation, clonal expansion, or 
through horizontal gene transfer from mobile elements6.  
The over-prescription of antibiotics in the clinic is one avenue for resistance 
development that requires reform. In some U.S. states, the number of prescribed courses 
of treatment with antibiotics each year exceeds the state’s population7. In other countries, 
antibiotics are available over-the-counter enabling unrestricted and unmonitored 
application. Studies have indicated that in 30-50% of cases, prescriptions are incorrect in 
the antibiotic agent chosen or in duration prescribed6.   
Antibiotics are also extensively used in the agricultural sector, administered to 
animals for the purposes of growth promotion and disease prevention. In the U.S., an 
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estimated 80% of the antibiotics sold are used for animal production purposes. This 
practice causes a multi-faceted problem as these antibiotics can select for resistant strains 
which can be transferred to consumers through food consumption and handling. Up to 
90% of the antibiotics administered to livestock are excreted through animal waste, 
which affects the environmental microbiome, by making their way into groundwater, 
fertilizers, and surface runoff6.  
The challenge and burden resistant infections pose to the global healthcare system 
calls for the development of new antibiotic technologies, along with reform in the 
distribution and use of existing therapies. Without immediate and coordinated action, the 
director of the Centers for Disease Control and Prevention noted ‘the medicine cabinet 
may be empty for patients with life-threatening infections in the coming months and 
years.’ 
1.2 Antimicrobial Peptides (AMPs): A Potential Antibiotic Alternative 
In light of the resistance crisis, antimicrobial peptides (AMPs) have gained 
increasing attention as potential antibiotic alternatives. AMPs are small peptides, 
typically less than 100 amino acids in size, which are produced by organisms across all 
domains of life as part of their innate immune response against microbial challenge8. 
Around 5,000 AMPS have been identified to date, displaying a large range in structural 
and functional diversity9. 
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The subset of bacterially produced AMPs, called bacteriocins, are especially 
attractive in the fight against antibiotic resistance. Bacteriocins are produced by microbes 
to ward of competing strains when resources are scarce10. It is estimated that the vast 
majority of bacteria produce at least one AMP10. The widespread dissemination of 
bacteriocins is likely linked to the fact that the genetic determinants underlying 
bacteriocin production tend to be found on mobile genetic elements such as conjugative 
plasmids and transposons. Their ubiquity in the bacterial kingdom, despite their 
associated production costs, emphasizes their functional utility11.   
Unlike eukaryotic AMPs, which tend to have broad spectrum activity and require 
micromolar concentrations for antibiotic effects, bacteriocins tend to have potent activity 
in the pico to nanomolar ranges against species within the same phylogenetic category as 
the producer11. The host strain is typically equipped with dedicated immunity genes to 
Figure 1-1 Select AMPs mechanism of action.  Mechanism of entry and action of several  
AMPs against (a) Gram-positive and (b) Gram-negative bacteria. (Reproduced from 
Duquesne et al. Nat. Prod. Rep., 2007, 24 with permission from The Royal Society of 
Chemistry.) 
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combat the toxic effect of the peptide. The fact that many bacteriocins have narrow 
spectrum activity offers the advantage that they won’t disrupt the commensal microbiota 
through off-target activity or apply a wide selective pressure for resistance development 
upon treatment, which are common drawbacks of broad spectrum antibiotics12.  
Figure 1 captures some of the diversity of bacteriocins and how they can differ 
from the level of target-cell entry down to their actual mechanism of antibacterial 
action13. Bacteriocins have been identified that exhibit specific activity against many 
clinical targets, including those which are antibiotic-resistant, such as methicillin-
resistant Staphylococcus aureus and vancomycin-resistant Enterococci12.  
However, despite all the therapeutic promise of AMP-therapy, there has been a 
large lack of clinical success. There are many challenges associated with AMP-based 
treatments, notably their susceptibility to proteolytic degradation and the costs associated 
with chemical synthesis. The primary commercial applications of AMPs have been 
limited to topical applications such as their use in dermal creams and mucosal delivery14. 
In this work, we propose a new technology to overcome the transport barriers of AMP-
therapeutics for use in treating bacterial infections that spring from the gastrointestinal 
(GI) tract.  
1.3 Recruiting Probiotics to Treat Enteric Infections 
1.3.1 Enteric Infections and Foodborne Illness 
Each year enteric infections, or those associated with the intestinal tract, cause an 
estimated 1.5 billion episodes of diarrheal disease and 2.2 million deaths worldwide. 
Enteric infections are the 5th leading cause of death among all ages globally, while the 
majority of fatalities occur in children under 5 years of age in developing countries. 
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These infections can be caused by an array of bacterial, viral, parasitic, and fungal agents 
that disrupt normal intestinal function15. 
Seventy percent of microbial diarrheal diseases are attributed to foodborne 
illnesses. The CDC estimates that in the U.S alone, there are 45 million cases of 
foodborne illness annually, which result in 128,000 hospitalizations and 3,000 deaths. 
The CDC predicts that 44% of the resulting hospitalizations and deaths are caused by 31 
known pathogens15.  
Effective vaccines have not been developed for many key enteric pathogens and 
antimicrobial therapy is complicated due to the resistance crisis. In agriculture, antibiotics 
have played a key role in controlling enteric infections in livestock, but many countries 
have imposed stricter regulations or banned the use of antibiotic in stock feeds to reduce 
microbial resistance emergence16.  
In light of the public health concerns with enteric infections, attention has been 
directed to the control, prevention, and detection of foodborne pathogens. The World 
Health Organization (WHO) has prioritized 22 agents for surveillance based on their 
higher prevalence, mobility, and mortality rates. These pathogens include Brucella spp., 
Campylobacter spp, Enteropathogenic E. coli, and Salmonella spp. (non-typhoidal). In 
the search for control strategies, the use of probiotic bacteria has been proposed as an 
antibiotic-alternative strategy to reduce and control foodborne pathogens15. 
1.3.2 The Role of Probiotics in Gastrointestinal (GI) Health 
Probiotics are live microorganisms that are believed to confer health benefits to 
their hosts upon consumption of adequate doses17. Although the beneficial effects of 
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probiotics have been speculated for centuries, they have recently gained increasing 
research attention with over 6,000 publications being released in the past two decades. 
Several mechanisms of actions that contribute to the positive effects of probiotics have 
been described, including their abilities to strengthen the intestinal barrier, modulate the 
host immune response, and produce antimicrobial substances18.  
The most common probiotics in use today are lactic acid bacteria (LAB), 
including Lactobacilli and Bifidobacteria, and non-pathogenic E. coli strains. During 
acute infections, the administration of probiotics may help combat pathogenic microbes 
through competitive exclusion and/or direct antagonism. There has been promising data 
elucidating the benefits of probiotics in combating enteric pathogens. For example, 
Lactobacilli and Bifidobacteria have been shown to enhance colonization resistance in 
mice infected with Campylobacter jejuni and Salmonella. Experimental administration of 
a strain of probiotic L. acidophilus was able to prevent cholera in both, mice and suckling 
rabbits15. 
Probiotics have additional benefits as a livestock feed additive. The use of 
probiotics as an animal feed supplement dates back to the 1970’s, with studies 
demonstrating their ability to increase performance and feed conversion efficacy in 
poultry and swine19.  
1.3.3 Engineered Probiotics as AMP-delivery vehicles 
With all the promise of both AMPs and probiotics for their individual potential as 
antibiotic alternatives in combatting enteric pathogens, we propose combining these two 
avenues and engineering probiotic bacteria as AMP-delivery vehicles.  
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Probiotics are attractive delivery platforms for AMPs as they are safe-to-consume, 
can survive transit to the GI tract, and naturally reside alongside the host’s intestinal 
microflora. Probiotics are amenable to genetic engineering and can be manipulated to 
produce and secrete these peptides at the local site of infection, overcoming the transport 
barriers associated with AMP-therapy. This work-flow enables a modular technology 
where the probiotic host and secreted AMPs can be combinatorially interchanged for 
different hosts and pathogens of interest.  
From an engineering standpoint, modified probiotics can enable tunable AMP 
expression, the production of multicistronic peptide constructs, and dosing regimens can 
be altered for both preventative and treatment methods. This proposed technology 
enables the therapeutic power of AMPs to be harnessed while utilizing the historic 
benefits of probiotics. 
1.4 Scope and Organization of Thesis 
This work details our recent advances on engineering probiotics for the treatment 
of pathogenic microbes. The work in this dissertation focuses on using the probiotic 
E.coli strain, Nissle 1917 (EcN), as a delivery vehicle for AMPs that target 
Enterobacteria, such as Salmonella and E. coli. We chose to focus on gram-negative 
pathogens as they remain notorious for antimicrobial resistance due to the presence of 
their outer membrane, which serves as an additional hurdle for antibiotic entry. The 
foundation of the work detailed in this dissertation focuses on incorporating and 
expanding upon existing synthetic biology tools and techniques for technological 
advancement. Although not the focus of this work, applying peptide engineering and 
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computational methodologies would greatly complement and enhance the improvement 
of engineered probiotics and opportunities for these methods are noted when applicable. 
In Chapter 2, we describe our development of a synthetic-hybrid promoter 
system, termed ProTeOn+, which enables robust and well-characterized gene expression. 
We focus on the application of this promoter network in modifying AMP biosynthetic 
gene clusters to increase secreted AMP titers from E. coli. However, it has many 
attractive features that could be used in general protein production when exogenous 
induction is undesirable. 
In Chapter 3, we describe our construction of an engineered probiotic, EcN(J25), 
for Salmonella control in poultry. We focus on the application of this system in the 
agricultural space, a sector where we believe engineered probiotics may have the most 
potential due to decreased regulatory barriers and an immediate need with stricter 
regulations being imposed on antibiotic use in livestock. In this work, we demonstrate the 
first in vivo success of AMP-producing probiotics, with our system reducing 97% of 
Salmonella carriage in infected turkey poults 14-days post treatment. A manuscript 
detailing this work is available in Nature’s Scientific Reports. 
Chapter 4 describes our collaboration with Dr. James Johnson of the Veterans 
Affairs (VA) Medical Center of Minneapolis in developing engineered probiotics for 
clinical applications. In this section we describe an engineered EcN derivative we 
developed, EcN(C7), that elicits strong antagonistic activity against the extraintestinal 
pathogenic E. coli strain, ST131, via production of Microcin C7 (Mcc7). Within the 
ST131 population, there is a resistant subset that is capable of evading the toxic effect of 
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Mcc7. We describe approaches we took to understand how this subset was exhibiting 
resistance, in hopes of finding and developing methods to eradicate this population. 
Chapter 5 describes our development and iterations of a modular peptide 
expression system that enables the release of multiple AMPs through a single AMP-
export system. The success of this system could enable the development of broader-
spectrum probiotics by releasing AMPs that target a multitude of pathogens or it could be 
used to release peptides with orthogonal mechanisms of action against a single target to 
decrease the chances of resistance development. 
Collectively, this thesis lays a foundation for future work in the field of 
engineered probiotics and discusses some of the challenges and potential that lay ahead. 
Along the way, we describe novel synthetic biology tools we have developed that can 
contribute to engineering bacteria for future applications outside of AMP-therapy. 
  
 
 
11 
 
Chapter 2 ProTeOn+: A Synthetic Promoter for the Delivery of 
Antimicrobial Peptides  
 
2.1 Scope 
With antibiotic-resistant pathogens emerging in the clinic with disconcerting 
frequency, the development of new antimicrobial technologies is sorely needed. 
Antimicrobial peptides (AMPs) offer a promising alternative to traditional antibiotics but 
remain largely limited in their utility due to their high costs of synthesis and susceptibility 
to proteolytic degradation. Engineering probiotic organisms as AMP production and 
delivery vehicles may overcome the barriers associated with AMP-therapy, allowing 
peptide release at the local site of infection. In this work, we describe a novel synthetic 
promoter system, termed ProTeOn+. This promoter demonstrates promise in improving 
titers of AMPs from engineered probiotics when incorporated in AMP biosynthetic gene 
clusters. ProTeOn+ has been characterized through a combination of experimental assays 
and stochastic kinetic models, eliciting well-defined and predictable behavior. We focus 
on using ProTeOn+ to re-engineer the Microcin V (MccV) operon, successfully 
increasing secreted MccV titers. ProTeOn+ is a useful tool in synthetic biology 
applications, laying a foundation for rationally designed promoters. Its well-defined 
behavior could help mitigate concerns over the use of live bio-therapeutics in disease 
control.  
2.2 Introduction 
Antimicrobial peptides (AMPs) are secreted natively from organisms across all 
evolutionary domains and constitute a principal defense mechanism against microbial 
challenge11. In the past few decades investigators have discovered hundreds of AMPs, 
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many of which elicit potent antimicrobial activity against clinically-relevant bacterial 
pathogens8. With a wide spectrum of structure and function, AMPs have been identified 
that effectively target bacteria by a multitude of molecular mechanisms, from 
compromising membrane integrity to targeting conserved intracellular components13.  
With the paucity of antibiotics in the drug-discovery pipeline coupled with the 
continuing emergence of antibiotic-resistant pathogens, AMPs have been proposed as a 
therapeutic alternative to conventional antibiotics20,21. However, despite their therapeutic 
promise, the medicinal power of AMPs has yet to be harnessed. The associated 
production costs, limited bioavailability profiles, and their propensity for proteolytic 
degradation has widely hampered the clinical success of AMP-therapy22,23.  
A host of bacterial infections spring from the intestinal tract, and AMP-releasing 
probiotics that prohibit or reverse pathogen colonization may constitute an effective 
antimicrobial strategy. Numerous examples are now available of probiotic organisms 
modified to express and secrete AMPs in vitro24–26. In the past few years, work has begun 
demonstrating the utility of these ‘antimicrobial probiotics’ at reducing pathogens such as 
Salmonella and Pseudomonas in the intestinal tracts of animals. These successful in vivo 
models have used the probiotic organism, E. coli Nissle 1917 (EcN), as the delivery 
strain27,28.  
 Interest in this technology has focused on its application as an animal feed 
supplement to reduce pathogen colonization in the intestinal tract of animals to replace 
antibiotic use in the feed. In lieu of tighter regulations on antibiotic use in food-
production, this could provide the agricultural industry with an alternative strategy to 
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protect livestock, improve food safety, and reduce microbial resistance development to 
clinically-relevant antibiotics29. 
There are many regulatory hurdles associated with the use of genetically modified 
live bio-therapeutics in animal feed formulations. Aside from implementing 
biocontainment strategies, the use of a well-characterized promoter system that allows 
predictive and defined behavior of the engineered component may help mitigate these 
concerns. Traditional E. coli promoters are challenging for in vivo applications as they 
can compromise cellular growth rate30, their induction can elicit bimodal population 
distributions31, and their performance can be affected by the carbon sources in the 
external environment32. In native AMP biosynthetic gene clusters, peptide expression is 
often activated by stress stimuli, such as glucose or iron depletion, to give bacterial hosts 
a competitive advantage in acquiring resources from the environment33. In the context of 
a therapeutic delivery system, an ideal promoter should enable robust peptide production 
that bypasses growth phase limitations and does not require expensive exogenous 
induction.  
In this work, we describe a novel synthetic promoter, termed ProTeOn+, which 
addresses many of the challenges associated with AMP-expression from E. coli. The 
ProTeOn+ promoter network is a strong constitutive promoter that has been extensively 
characterized through experimental assays and stochastic simulations. This promoter 
system enables strong peptide expression in all phases of growth but is designed to reach 
peak expression levels upon entry into stationary phase. Many AMPs enter sensitive cells 
through receptors that mediate nutrient transport, many of which are upregulated in 
nutrient limiting environments, such as stationary phase. This upregulation of AMP 
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importers likely contributes to the increased susceptibility of target cells to AMPs in 
these environments, and ProTeOn+ capitalizes on this feature by increasing production in 
this phase of growth.  
The ProTeOn+ promoter has been used successfully in engineering EcN to 
produce a variety of different AMPs, and led to the first in vivo success of engineered 
EcN at reducing pathogens in the gastrointestinal (GI) tract of animals34. Herein, we 
describe the mechanics of the ProTeOn+ promoter and compare its expression capacity to 
commercial and native AMP promoters. We also show how redesigning the operon of 
Microcin V, one of the most studied AMPs to date, with this system can lead to 
improvements in secreted AMP titers. 
2.3 Results 
2.3.1 ProTeOn+ Network Mechanics 
A schematic of the ProTeOn+ promoter system is depicted in Figure 2-1a. The 
core component of this network is the synthetic-hybrid activator protein, ProTeOn, which 
was first developed by Volzing et al.30.  
ProTeOn is a synthetic protein that was constructed using components of the 
native bacterial tetracycline resistance (tet) and luminescence (lux) operons. ProTeOn 
consists of two functional domains, linked together by a flexible polypeptide chain. The 
N’-terminal region of ProTeOn serves as the DNA-binding component and is composed 
of the reverse-tetracycline repressor (rTetR). rTetR is a reverse phenotype mutant of the 
regulatory tetracycline repressor (TetR) and binds specifically to the tetO DNA operator 
site35. The C’-terminal region of ProTeOn consists of LuxRΔN(2-162) (LuxRΔN), which 
is the constitutive activating component of the full-length LuxR regulatory protein. LuxR 
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is a well-studied transcriptional activator derived from the quorum-sensing luminescence 
operon of Vibrio fischeri 36. LuxR binds specifically to the luxbox operator site and 
upregulates downstream gene expression through RNA polymerase (RNAP) recruitment 
to the promoter region.  
The associated synthetic promoter, Pon, contains tetO and luxbox binding regions 
that are optimally spaced to facilitate strong interactions with the ProTeOn activator37. 
Upon binding Tc, or equivalently, anhydrotetracycline (aTc), the rTetR domain of 
ProTeOn undergoes a conformational change that enables stronger binding with the tetO 
site. This DNA binding event brings the attached LuxRΔN component in contact with the 
luxbox operator to promote its activating effect.  
In the original AND-gate design (Figure 2-1b), expression of the output signal, 
green fluorescent protein (GFP), relies on induction with both isopropyl β-D-1-
thiogalactopyranoside (IPTG) and aTc. In the ProTeOn+ network described herein, the 
activator is placed under the control of its own dedicated promoter site (Pon), generating 
a positive feedback control element. In this configuration, the ProTeOn activator 
overcomes the requirement for exogenous induction for protein expression. We 
anticipated a stronger expression profile with this configuration than the predecessor 
 Figure 2-1. Schematics of network configurations. (a) ProTeOn+ (b) ProTeOn AND-
Gate 
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system and expected the ProTeOn activator to accumulate in cells allowing for dramatic 
increases in protein production upon deceleration of cellular growth rate. Using GFP as a 
reporter gene, we compared the expression profiles of the ProTeOn AND-Gate and the 
ProTeOn+ promoter systems using kinetic spectrophometric measurements.  
Figure 2-2 shows the expression profiles of the AND-gate in the ‘ON’ (0.5mM 
IPTG, 100ng/ml aTc) and ‘OFF’ (0mM IPTG, 0ng/ml aTc) states in comparison to 
ProTeOn+ over a range of cell densities. The ProTeOn-AND gate elicits tight inducible 
expression, while the ProTeOn+ system consistently outperforms the predecessor system 
Figure 2-2. Comparison of ProTeOn+ and AND-Gate expression profiles. The AND-
Gate shows tight inducible expression with negligible expression in the uninduced state 
(0mM IPTG, 0ng/ml aTc) and significant increases in the ‘ON’ state (0.5mM IPTG, 
100ng/ml aTc). ProTeOn+ (no inducer) outcompetes the fully induced AND-gate across 
all measurements. The error bar represent the standard error of 3 replicates. 
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in terms of fluorescence and swells to remarkable output levels in late logarithmic phase.  
Between OD 0.5 and 1, the fluorescent signal of ProTeOn+ increases 4-fold. A  
comparison of these two systems with more experimental conditions is available in 
Appendix A (Figure 8-1). 
To put the expression strength of ProTeOn+ in context, Figure 2-3 shows a 
comparison of ProTeOn+ to two commercially available promoters, OXB20 and the 
fully-induced T7 RNAP/promoter system. OXB20 is a derivative of the LexA-dependent 
RecA promoter and is the strongest constitutive promoter available from Oxford 
Genetics. The T7 system is a highly efficient and tightly-inducible promoter system that 
Figure 2-3. Comparison of ProTeOn+ to commercially available promoters.  GFP 
expression was kinetically monitored from T7express cells under the control of the 
ProTeOn+, OXB20, and T7 promoters. The T7 promoter is fully-induced with 1mM 
IPTG. Fluorescence readings (left) were measured every 4hrs and OD600 readings (right) 
were taken on 80min intervals for 20hrs. Error bars are standard error of four replicates. 
 
 
 
18 
 
is widely-used for expression of cloned genes in E. coli. The system utilizes the T7 phage 
RNAP promoter which selectively transcribes from a dedicated T7 promoter site38. 
In this comparison, ProTeOn+ is competitive with the fully-induced T7 system in 
the resulting fluorescence signal without the associated growth burden. Although T7 does 
slightly outcompete ProTeOn+ in production, the primary advantage of ProTeOn+ is that 
is does not require external induction; which in the context of AMP-expressing probiotics 
eliminates issues with inducer cost and potential toxicity in vivo.  
2.3.2 Stochastic-Kinetic Simulations of ProTeOn+ 
The network components of the ProTeOn+ expression circuit are well-
characterized, and many of the known functional interactions have readily available 
kinetic information39–45. Using these values, it is possible to model the molecular 
mechanisms that underlie the observed phenotype, offering a more detailed 
understanding of system behavior. To our knowledge, this level of detail is not available 
for any other bacterial promoter system, making ProTeOn+ an attractive platform for 
genetically modified organisms and therapeutic technologies. 
 As biological reactions tend to occur away from the thermodynamic limit, we 
conducted stochastic simulations to describe the expression profiles of ProTeOn+. These 
simulations generate probability distributions of molecular concentrations which are 
directly comparable to experimentally observed fluorescence populations46.  
The model presented in this work takes into account each bimolecular interaction 
event that underlies the resulting GFP output signal. As aTc is capable of strengthening 
ProTeOn’s interactions with the tetO site within the promoter, we chose to include aTc-
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induced samples in our simulations to capture any effects induction would have on 
system output to give better insight into the sensitivity of the in silico analysis. The 
theoretical reaction network used in these models is displayed in Table 2-1 and details 
each reaction involved in GFP output, from the initial induction step to final protein 
maturation.  
The kinetic constants displayed were found from a review of the literature39–45. aFirst order 
reaction rates have units of s-1, bsecond order reaction rates have units of (MS)-1, cthird order 
reaction rates have units of 1/s, dtranscription and translation reactions are Gamma 
distributed109. The GFP and PROTET genes have 717 and 1065 base pairs, or 239 and 355 
amino acids, respectively37,110. Hence, the total amount of transcribed base pairs is 1782. The 
reaction rate units are s-1, *reaction rates have been modified to fit the experimental results. 
Table 2-1 Biomolecular Reaction Network 
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The model was used to generate the fluorescent population dynamics of cells 
containing ProTeOn+ upon induction with 0, 10, and 200ng/ml of aTc at 1, 3, 5, and 7 
hours post-induction during exponential growth phase.  The results were compared to 
experimentally observed fluorescence populations under the same conditions.  
 
Figure 2-4. Comparison of ProTeOn+ GFP expression from flow cytometry and 
stochastic simulations. The figures on the left are the experimental results and the figures 
on the right show the simulation predictions. The top panel shows the average 
intracellular fluorescence of cells induced with 0, 10, and 200ng/ml aTc at 1, 3, 5, and 
7hrs post-induction. The simulation results match the relative behavior of the 
experimental results across all time points. The bottom panel shows the population 
distributions obtained by the simulations and flow cytometry when they reach their 
steady-state profiles at 7hrs. 
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As shown in Figure 2-4, the in silico results match both the dynamic behavior of 
the GFP production dynamics observed experimentally and the absolute production at 
steady state (7hrs). Although the feedback control element mitigates the induction effect 
of aTc and leads to only modest increases in GFP signal, these signal changes were 
accurately captured in our models. More detailed information on the model development 
can be found in Appendix A.  
2.3.3 Incorporate ProTeOn+ into MccV-gene cluster 
Most promoters driving AMP expression in native constructs are activated by 
stress signals to give producers a competitive advantage in survival. MccV, formerly 
known as Colicin V, was the first antibiotic substance reported to be produced by E. coli 
and elicits antagonistic activity against closely related species13. MccV elicits antibiotic 
activity on sensitive cells by targeting the outer membrane Cir receptor and disrupting 
membrane potential13.  
The genetic organization of the MccV operon is depicted in Figure 2-5. The 
MccV gene cluster is 4.2kb long and contains two converging operons. One operon 
dictates expression of the genes, cvaC and cvi, which encode for the MccV precursor and 
self-immunity gene, respectively. The second operon contains the sequences for the 
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export machinery, including cvaB, the ABC transporter, and cvaA, the required accessory 
protein13.  
Previous work has demonstrated that the promoters upstream of cvi, i.e., P1, and 
cvaA, i.e., P2, are both iron regulated47. In this work, we compared the promoter strengths 
of ProTeOn+, P1, and P2 using GFP (Figure 2-6). Using the same spectrophometric 
growth assay described previously, we measured the fluorescence of each cell culture 
over time as function of cell density. The results of this assay are shown in Figure 2-6 
comparing MC1061 E. coli cells expressing GFP from both, ProTeOn+ and P1. 
ProTeOn+ maintains consistently higher fluorescence levels, whereas P1 demonstrates 
minimal levels of expression until cells reach a higher optical density (OD~0.8-0.9). At 
Figure 2-5. Engineered Gene Clusters for MccV Production.  
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late logarithmic phase, the P1 promoter abruptly increases its production capacity. The 
results for the ProTeOn+ and P2 comparison can be found in Appendix A (Figure 8-2). 
We calculated the promoter strengths of ProTeOn+ and P1 in both exponential 
and stationary phase using the method detailed by Mutalik et al.48. From these results, it 
was determined that the exponential phase promoter strength of ProTeOn+ was over 7.5-
fold higher than P1. In stationary phase, the strength of both promoter increases 
dramatically with 6x and 19x increases for ProTeOn+ and P1, respectively (Figure 2-7). 
However, even with the sharp activation of the P1 promoter in late-logarithmic phase, the 
ProTeOn+ system continues to elicit higher expression levels at all times.   
Figure 2-6. Comparison of ProTeOn+ and P1 promoters. GFP was placed downstream 
of ProTeOn+ and P1 and fluorescence was measured at 30min intervals for 24hrs and 
plotted as function of OD600. Error bars are standard error of four replicates. 
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 To test if these increases in promoter strength could translate to higher levels of 
secreted MccV when using ProTeOn+ to drive expression, we created the plasmids 
pBFG4 and pBFG5 which contain the corresponding gene clusters, depicted in Figure 2-
5. These respective gene networks were cloned into a pMS expression vector containing a 
Spectinomycin resistance marker and ColE1 origin of replication (Appendix A).  
 Compared to the native construct, we swapped the organization of the four genes 
of the MccV operon into a linear organization with all genes being encoded in the same 
orientation. We interchanged the respective positions of cvaC and cvi and altered the 
upstream ribosomal binding sites on each. The only difference between pBFG4 and 
 
Figure 2-7. Promoter Strength of ProTeOn+ and P1.  Strength calculated in exponential 
(left) and stationary (right) phases. 
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pBFG5 is the presence of the promoter upstream of cvi.  
To test the secretion capacity of these constructs, we expressed pBFG4 and 
pBFG5 in M1061 E. coli (strains BFG4 and BFG5, respectively) and evaluated the 
relative levels of external MccV at the end of exponential and stationary phase. To 
evaluate the amount of MccV secreted in exponential phase, we inoculated washed BFG4 
and BFG5 cells to OD~0.1. When the cultures reached the end of growth phase (set at 
OD~2), the supernatant was collected and tested for antimicrobial activity using liquid 
supernatant inhibition assays. The supernatant from each producer was applied to a 
culture of DH5α, a sensitive indicator strain, at 10% of the total volume and growth was 
Figure 2-8. Inhibitory activity of MccV secreted by strains BFG4 and BFG5 during 
exponential phase growth.  Supernatant containing secreted MccV was collected 
from BFG4 and BFG5 at OD~2. 10% supernatant was applied to DH5α from BFG4, 
and BFG5 and growth was monitored by OD600 readings for 14hrs. A control group 
was treated with 10% supernatant collected from empty MC1061 cells (LB). The 
errors bars are standard error of three replicates. 
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monitored for evidence of inhibition. The resulting growth curves are shown in Figure 2-
8. From this assay, the treatment with the supernatant collected from BFG5 led to the 
greatest inhibition of DH5α indicating higher concentrations of MccV. 
To test the secreted MccV at the end of stationary phase, we used an agar 
diffusion assay. At 16hrs post inoculation, we collected the supernatant from BFG4 and 
BFG5. The supernatant was serially diluted and spotted on agar plates seeded with DH5α. 
Using the method described by Solbiati et al., we were able to calculate the minimum 
inhibitory concentration (MIC) of supernatant required for growth inhibition in terms of 
Bacteriocin Units (BU)49. A BU is defined as the reciprocal of the final dilution that 
inhibits growth of the indicator strain. For BFG4 the MIC was 6 BUs and for BFG5 was 
2 BUs, consistent with our previous results. 
We note that we developed the construct, pBFG6, by placing the Pon promoter 
upstream of both, cvi and cvaA. However, this arrangement dramatically decreased 
peptide secretion as determined by an agar diffusion assay. We hypothesize that 
increasing the transporter levels may affect membrane permeability and integrity making 
this an unfeasible engineering route. 
2.4 Discussion 
AMPs are a largely untapped reservoir of antibiotic activity that remain hindered 
in their therapeutic application due to their inherent economic and transport barriers. In 
this work, we propose recruiting and redesigning bacteria as peptide delivery vehicles to 
enable localized production of otherwise undeliverable AMPs. 
 
 
27 
 
  The success of AMP-producing bacteria lies largely in the underlying gene 
expression circuits that dictate peptide expression and secretion. Herein, we describe our 
development of a new synthetic biology tool, the ProTeOn+ promoter, for use in AMP-
delivery applications. ProTeOn+ is competitive with commercial promoters in terms of 
protein production but has the advantage of being fully characterized through a 
combination of experimental and computational techniques eliciting well-defined and 
predictable behavior.  
We have used ProTeOn+ to improve MccV titers from its native biosynthetic 
gene cluster. The use of ProTeOn+ in this context enables increased peptide secretion in 
both primary phases of growth, which translates to greater inhibitory activity. With the 
recent advances in the successful use of AMP-producing probiotics, this study offers a 
stepping stone in the pathway of rationally designing AMP gene clusters.  
2.5 Materials and Methods 
2.5.1 Bacterial Strains and Plasmid Construction 
The Pon promoter, ProTeOn activator, and GFPmut3 sequences were synthesized by 
GENEART in a pMS expression vector containing a ColE1 origin of replication and 
Spectinomycin resistance gene (pBFmut3). A detailed plasmid map is available in 
Appendix A. The ProTeOn AND-Gate vector maps and construction methods are 
detailed in ref. 30. Both networks were transformed into chemically competent 
BL21(DE3) cells (Sigma Aldrich) via heat-shock for the fluorescence assays. 
Plasmids pBFG4, pBFG5, and pBFG6 (maps in Appendix A) were constructed by 
amplifying cvaA and cvaB from pHK22 (donated by Professor Kolter, Harvard 
University) and inserting them into pBFmut3 in place of GFP using NEBuilder® HiFi 
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DNA Assembly Master Mix (HiFi, NEB). A gene fragment was synthesized from 
Integrated DNA technologies (IDT) containing cvaC and cvi with the ribosomal binding 
sites (AGGAGGA) upstream of both genes. This gene was inserted downstream of 
ProTeOn to create pBFG5. The ProTeOn+ promoter site was removed and replaced with 
the P1 promoter, which was synthesized by IDT for the development of pBFG4 via HiFi. 
For pBFG6, the Pon promoter sequence was synthetized by IDT and inserted in place of 
P1 via HiFi assembly. pBFG4, pBFG5, and pBFG6 were expressed in MC1061 E. coli 
(Lucigen) for all work presented (strains BFG4, BFG5, BFG6, respectively). 
2.5.2 Spectrophotometer Fluorescence Assays  
BL21(DE3) cells containing the ProTeOn AND-Gate and ProTeOn+ networks were 
grown overnight in selective Luria-Bertani (LB) media at 37°C with agitation at 225rpm. 
1.5ml of the overnight cultures were transferred to a 2ml microcentrifuge tube. The cells 
were washed twice by centrifuging for 2 min @ 2.5rcf and resuspended in 500µl of fresh 
LB. Cultures were diluted to 104 CFU/ml and transferred to a sterile, black-walled 96-
well plate (CellVis) in 10µl volumes. LB media containing varying levels of IPTG and 
aTc (0-1mM IPTG, 0-200 ng/ml aTc) were added, bringing the final volume to 
350µl/well with four replicates per treatment.  
Fluorescence (Ex 485, Em 528, gain 100) and optical density (600nm) measurements 
were taken every 15-20 mins in a Biotek Synergy H1 microplate reader maintained at 
37°C in double-orbital mode. Wells containing empty cells and LB-only were assayed in 
parallel to correct for auto-fluorescence and background absorbance from the media. The 
OD600 reading of each sample was blanked to correct for LB background and the 
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fluorescence was corrected by subtracting the average reading of the empty BL21 cells as 
a function of OD. 
For the OXB20, ProTeOn+, and T7 promoter comparison, T7-express cells containing 
the pSF_PonMut3, pSF_OXBmut3, and pSF_T7mut3 plasmids (Appendix A) were 
grown in selective LB media containing 50µg/ml Kanamycin overnight. OD readings 
were taken every 80 mins and fluorescence on 4hr intervals. OD600 and fluorescence 
measurements are shown without additional corrections. 
2.5.3 GFP Quantification via Flow cytometry 
Overnight cultures of BL21(DE3) cells containing the ProTeOn+ network were diluted 
1:10 in selective LB media. After 2 hours of growth, the cells were inoculated in LB 
media containing 0, 10, or 200 ng/ml aTc at an OD~0.1 with 4 replicates per treatment. 
All cultures were maintained at 37°C with agitation at 225rpm for the duration of the 
experiment. Samples were monitored for growth by OD600 and were diluted 1:10 on 2-
hour intervals to restrict growth to logarithmic phase. At 0, 1, 3, 5, and 7 hours post-
induction, 0.1ml of cells was collected from each sample. The harvested cells were 
centrifuged for 3min @2.5rcf and fixed with 4% paraformaldehyde (PFA, Affymetrix) 
for 30 mins to halt GFP production and degradation following harvest. Samples were 
then centrifuged and resuspended in 0.25ml of phosphate buffer saline (PBS, Teknova) 
and stored at 4°C until analysis. 
GFP fluorescence was measured using a BD Accuri C6 flow cytometer. For each sample, 
25,000 gated events were collected and analyzed using BD Biosciences software.  
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2.5.4 Stochastic chemical reaction simulations 
The theoretical reaction network (Table 2-1) was created in order to simulate the 
experimentally observed behavior of the ProTeOn+ promoter system. To simulate the 
kinetic equations, a hybrid stochastic-discrete and stochastic-continuous algorithm, 
Hy3S, was implemented50,51. In the past, Hy3S has been employed for the simulation of 
multiple different biological systems35-39. Hy3S solves the system by coupling chemical 
Langevin equations with discrete kinetic Monte Carlo methods52.  Milstein’s method was 
used and 100,000 trajectories were simulated per aTc treatment50,51. More detailed 
information on model development and parameters in available in Appendix A. 
2.5.5 Liquid Supernatant Activity Assays 
1ml of overnight cultures of BFG4, BFG5, and empty MC1061F’ cells were collected 
and centrifuged for 3min @ 2.5rcf. The supernatant was decanted and the pellet was 
resuspended in 2ml LB. Replicate cultures of each strain were diluted to an OD~0.1 in 
2ml LB. When the cultures reached an OD~2, 1ml of each culture was transferred to a 
microcentrifuge tube and centrifuged for 1min @13.5rcf. The supernatant was collected 
and sterilized using a .22µm filter.  
In a 96-well plate, 180µl of 104 CFU/ml DH5α was transferred to each well. The 
collected supernatant from each strain and replicate was diluted in spent media from 
MC1061 and applied to DH5α bringing the total supernatant treatment to 10%. The 
OD600 was measured on 20-min intervals using a Biotek Synergy H1 microplate reader 
that was maintained at 37°C in double-orbital mode.  
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2.5.6 Agar Diffusion Assay 
Supernatant was collected from replicate overnight cultures (16hrs) of BFG4, BFG5, 
BFG6, and empty MC1061 cells. The supernatants from BFG4, BFG5, andBFG6 were 
two-fold serially diluted into spent media from MC1061. LB agar plates containing 200µl 
of OD~0.5 DH5α per 40ml media were spotted with 10µl of each subsequent serial 
dilution. The plates were incubated for 24 hours and zones of inhibition were evaluated. 
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Chapter 3 Antimicrobial Probiotics Reduce Salmonella enterica in 
Turkey Gastrointestinal Tracts 
 
Adapted from “Forkus, B., Ritter, S., Vlysidis, M., Geldart, K., & Kaznessis, Y. N. (2017). 
Antimicrobial Probiotics Reduce Salmonella enterica in Turkey Gastrointestinal Tracts. 
Scientific Reports, 7.” 
3.1 Scope 
Despite the arsenal of technologies employed to control foodborne nontyphoidal 
Salmonella (NTS), infections have not declined in decades. Poultry is the primary source 
of NTS outbreaks, as well as the fastest growing meat sector worldwide. With recent 
FDA rules for phasing-out antibiotics in animal production, pressure is mounting to 
develop new pathogen reduction strategies. 
We report on a technology to reduce Salmonella enteritidis in poultry. We 
engineered probiotic E.coli Nissle 1917, to express and secrete the antimicrobial peptide, 
Microcin J25. Using in vitro experiments and an animal model of 300 turkeys, we 
establish the efficacy of this technology. Salmonella more rapidly clear the ceca of birds 
administered the modified probiotic than all other treatment groups.  Approximately 97% 
lower Salmonella carriage is measured in the treated group, 14 days post-Salmonella 
challenge.  
Probiotic bacteria are generally regarded as safe to consume, are bile-resistant, 
and can plausibly be modified to produce a panoply of now-known antimicrobial 
peptides. The reported systems may provide a foundation for platforms to launch 
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antimicrobials against gastrointestinal tract pathogens, including ones that are multi-drug 
resistant. 
3.2 Introduction 
Foodborne gastrointestinal (GI) tract infections exact a vast global health toll, with 
nearly one in ten individuals falling ill each year 53. In the U.S., non-typhoidal Salmonella 
(NTS) is responsible for the highest incidence of foodborne disease among bacterial 
pathogens, causing one million infections, 19,000 hospitalizations and over 400 deaths 
annually 54,55. 
Poultry is a major reservoir for NTS, with more than half of outbreaks linked to the 
consumption of contaminated poultry products 54. In particular, Salmonella enterica 
serovar Enteritidis (SE) is the most common NTS strain in the U.S. food supply 54. 
Poultry are asymptomatic carriers of SE, which allows rapid transmission through flocks. 
Subsequent spread to the community can occur at many stages along the food-production 
chain, but primarily at the consumption level 56.  
A related public health concern is the continuing emergence of antibiotic-resistant 
foodborne pathogens. The Centers for Disease Control and Prevention have estimated 
that 5% of NTS infections are already resistant to 5 or more antibiotics, and have 
classified NTS as a ‘serious threat’ to public health 55. Resistant infections complicate 
patient treatment leading to prolonged illnesses, increased mortality rates, and higher 
medical expenses 55. 
This widespread resistance development is partly attributed to the heavy use of 
antibiotics in animal production 57. Over 70% of the antibiotics produced in the U.S. are 
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incorporated in livestock feed 58. It is plausible that this continuous, sub-therapeutic 
administration applies selective pressures that facilitate the evolution of resistance 
development. Resistant strains may then be released to the environment through fecal 
shedding, human handling, and consumed foods57. This microbial release is concerning 
because there is considerable overlap between the antibiotics listed by the World Health 
Organizations as ‘critically important’ for human health and animal health. 
With these concerns, pressure is mounting to phase out the nontherapeutic use of 
antibiotics in U.S. food production 29. Proposals to legislate feed-grade antibiotic removal 
have been met with significant opposition because a complete ban could lead to increased 
food prices and strain current agricultural practices 57. Instead, the FDA issued a rule on 
livestock use with the agreement of animal pharmaceutical companies. According to this 
plan, drug companies will voluntarily revise the FDA-approved labeled use conditions, 
and change the marketing status from over-the-counter to Veterinary Feed Directive for 
drugs administered through feed or to prescription status for drugs administered through 
water. The ultimate goal is to promote the judicious use of medically important 
antimicrobial drugs in food animals and to remove the use of antimicrobial drugs for 
production purposes 29.  
Antibiotics in animal feed prevent or reduce the incidence of infectious disease 57. 
Therefore, it may be surmised that with the imminent phasing-out process, alternative, 
affordable pathogen reduction technologies are needed to help mitigate consumer risk 
and exposure to foodborne pathogens. 
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We present tests of a modified probiotic E. coli strain, Nissle 1917 (EcN), with the 
capacity to reduce SE counts in the GI tract of turkeys. Using recombinant DNA 
technology, we modified EcN to produce and secrete the antimicrobial peptide (AMP), 
Microcin J25 (MccJ25). We show in two repeat studies that the modified probiotic 
(EcN(J25)) can substantially reduce SE counts in the ceca of turkeys. With the 
administration of a single dose, we observe markedly improved SE clearance rates over a 
two-week period compared to treatment with the antibiotic, enrofloxacin (ENR), or the 
unmodified EcN. 
Beneficial bacteria have been used in the agricultural industry for years to improve 
animal health and limit pathogen colonization. Often administered as competitive 
exclusion products, commercial treatments have been developed that are routinely 
administered to newly hatched birds 59. Probiotic formulations have also been tested as 
feed additives. When incorporated in livestock diets, probiotics can improve animal 
growth, feed conversion efficiency 60, and reduce shedding of enteric pathogens 61.  
Herein we show in two repeat trials that a modified probiotic (EcN(J25)) can 
substantially reduce SE counts in the GI tract of turkey poults. We observe markedly 
improved SE clearance rates over a two-week period compared to the traditional 
antibiotic enrofloxacin or the unmodified EcN. 
3.3 Design of System for AMP Production and Secretion 
Our objective is to lower SE carriage in the GI tract of poultry by employing 
probiotic EcN as the production and delivery vehicle of MccJ25. MccJ25 is a 21-residue 
peptide 62 natively secreted from the human E. coli isolate AY2549. MccJ25 elicits a 
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strong antagonistic affect against SE. Mature MccJ25 forms a lasso structure62, affording 
remarkable stability against unfolding and degradation. The peptide inhibits bacterial 
growth primarily by binding to RNA polymerase and obstructing nucleotide uptake 63.  
The four genes facilitating production of the microcin, i.e., mcjA, mcjB, mcjC, and 
mcjD, are located adjacently on a native plasmid-borne operon (Figure 3-1)49.  mcjA 
encodes the MccJ25 precursor that is processed into the active form by enzymes, McjB 
and McjC 64. The immunity protein, McjD, enables the active efflux of the peptide to the 
extracellular space 64. Natively, mcjA expression is governed by an ill-defined promoter 
that initiates production upon entry into stationary phase, with maximal expression in 
conditions of nutrient depletion. The other genes are hypothesized to be constitutively 
expressed 65 .  
Figure 3-1 Schematic of native and engineered MccJ25 operons. In the natural gene 
cluster, mcjA is divergently expressed from its dedicated processing and transport 
enzymes. Expression of mcjA is activated in stationary phase while mcjBCD are 
constitutively expressed by a σ70-like promoter. pBF25 is the engineered construct used 
in this study where mcjA production is under the control of the ProTeOn+ system and 
all genes are convergently expressed. 
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In this work, we engineered a strong promoter system to bypass native limitations on 
mcjA production. Expanding upon the synthetic ProTeOn system, a hybrid protein-
promoter pair developed by Volzing and co-workers 37, we designed ‘ProTeOn+’, a new 
genetic circuit, which enables constitutive, high-level production of downstream genes. 
ProTeOn is a synthetic activator protein constructed by physically linking the reverse 
tetracycline repressor protein to the activating domain of the LuxR transcription factor of 
Vibrio fischeri. ProTeOn makes strong contacts within the engineered DNA promoter site 
(Pon), which contains optimally spaced tetracycline and LuxR operator binding regions. 
This system recruits RNA polymerase and strengthens the holoenzyme-DNA interactions 
to strongly up-regulate gene expression 37.  
In ProTeOn+, we incorporated the ProTeOn protein in a positive-feedback control 
loop, allowing it to amplify its own production while driving expression of a target 
protein (Figure 3-1). We incorporated ProTeOn+ upstream of mcjA and reorganized the 
genes to be convergently expressed, creating pBF25 (Appendix B). This system achieves 
more robust gene expression than previously afforded and has a markedly stronger 
expression capacity than the strong, commercial promoter, OXB20 (Chapter 2). 
3.4 Results 
3.4.1 In Vitro SE Growth Inhibition 
To evaluate the antimicrobial potency of the engineered gene expression cassette, 
pBF25 was expressed in Nissle (EcN(J25)). As shown in Figure 3-2a, EcN(J25) exhibits 
clear microcin activity after just 2 hours of culture growth and the peptide continues to 
accumulate in the supernatant over time. In contrast to the native promoter, the 
ProTeOn+ system affords microcin production across all stages of growth.  
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Figure 3-2a demonstrates that microcin-containing supernatant (SN) produced by 
EcN(J25) inhibits SE growth. The assay shows kinetic growth curves of SE in the 
presence of small volume fractions of MccJ25-rich SN. The two microcin-containing 
treatments (0.5 and 1%) exhibit considerable growth suppression compared to the control 
(0%) after just 4 hours of exposure (p<0.05). 
Figure 3-2 Modified probiotic elicits strong antagonistic activity against SE  (a) pBF25 
enables growth phase independent production of MccJ25. The growth (OD600) of EcN(J25) 
is shown as a function of time. Supernatant was collected from EcN(J25) at 0, 2, 5, 10 and 
20hrs following inoculation in fresh media. Two-fold serial dilutions of the supernatant were 
plated on SE-agar plates and the reciprocal of the final dilution with a visible halo was denoted 
as the activity units (AU). Microcin production from the modified Nissle commences 
immediately upon inoculation with visible activity after just 2 hrs. (The connecting lines used 
are for visualization purposes and are not interpolations of the data points.) (b) Kinetic growth 
inhibition of SE in the presence of supernatant from the modified probiotic strain. SE is grown 
in the presence of 0, 0.5, and 1% volume fractions of supernatant collected from EcN(J25), 
demonstrating a strong antimicrobial effect. 
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3.4.2 SE reduction in turkey ceca following EcN(J25) treatment 
To test the efficacy of the modified probiotic at reducing colonization of SE in the GI 
tract, we performed two independent treatment trials in turkey poults. We focused on 
pathogen clearance in the ceca because they are the primary area of bacterial residence 
within the poultry GI tract, harboring over 1011 organisms per gram of digesta 66. The 
function of the ceca is to provide a stable bacterial ecosystem, and aid in feed 
fermentation and digestive processes. The ceca are the principal colonization site of 
Salmonella and are a major source of contamination in processing facilities 67,68. 
Reducing Salmonella levels in the ceca at the pre-harvest stage may decrease the amount 
that initially enters the food chain. 
We challenged turkey poults at 4 days post-hatch with a 1ml oral gavage of 108 
colony forming units (CFU) of SE (day 0), followed on day 1 by treatment with 1ml of 
either 108 CFU EcN, 108 CFU EcN(J25), or PBS (phosphate buffer saline). These primary 
treatment groups allowed for comparison between the modified probiotic’s engineered 
antimicrobial activity and any inherent competitive exclusion or native antagonistic effect 
of the unmodified strain. The SE strain used, MH91989, was previously isolated from a 
chicken GI tract and is known to colonize poultry intestines. 
Over a two-week period, we extracted the ceca from birds at 5 time points post SE-
infection and enumerated the SE and Nissle count densities. Figure 3-3 shows the 
trajectories of the SE counts for each individual treatment group throughout each of the 
studies. In both trials, all SE counts declined for all groups over the two-week trial.  
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In Trial 1, the SE counts in the EcN(J25)-treated birds were significantly reduced 
compared to the untreated birds (p=.03, see Materials and Methods). By the final time 
point (day 14), the SE counts were reduced by over an order of magnitude, with SE being 
reduced by a factor of 25 compared to the SE-control group. Trajectories displaying 
individual bird counts for both challenge strains can be found in Appendix B. 
Figure 3-3. SE reduction in the ceca of turkey poults administered the EcN(J25) 
treatment. Turkey poults at 4 days post-hatch (day 0) were challenged with 108 CFU 
of SE. On day 1, birds were treated with PBS, EcN(J25), EcN, or ENR (Trial 2 only). 
3–8 birds were euthanized from each treatment group 2, 4, 7, 10, and 14 days post-
infection. SE and EcN were enumerated using selective plating to determine CFU per 
gram of ceca. The average SE counts at each necropsy point are shown for each 
treatment group at each time point for both trials. Time course line thickness represents 
the standard error. Both trials were analyzed separately using ANOVA and post-hoc 
analysis was performed for pairwise comparisons. More detailed descriptions of the 
statistical analysis can be found in the Materials and Methods. 
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The differences between the SE-reduction trends in the two trials can be attributed to 
slightly different experimental parameters. In Trial 2, the crinoline flooring in the isolator 
units was removed on day 1 to mitigate any reinfection process caused by coprofagia. In 
Trial 1 this flooring was removed on day 4. The earlier removal in Trial 2 may explain 
the rapid 10x reduction of SE observed at the first collection point in the EcN(J25)-birds, 
absent in Trial 1. We note that fecal shedding within housing facilities and subsequent 
ingestion have been implicated as the primary route of horizontal pathogen transmission 
69. We hypothesize that any SE-reduction effect attributed to the more sanitary conditions 
created by the removal of the crinoline flooring may be more efficacious than the 
probiotic treatment in controlling SE. In Trial 2, all treatment groups, excluding the ENR-
group, experience a dramatic decrease in SE counts by day 4, alluding to expedited 
pathogen shedding in this more hygienic environment. 
In both trials, the unmodified Nissle did not by itself yield a significant reduction in 
SE counts. This result demonstrates that MccJ25 activity was responsible for the faster 
clearance rate from the ceca.  
In Trial 2, we compared the efficacy of the EcN(J25) treatment to the activity of a 
single dose of enrofloxacin (ENR), a fluoroquinolone antibiotic. As shown in Figure 3-3, 
the ENR treatment led to significantly higher SE levels than all other treatment groups (p 
≤ .02, see Materials and Methods). 
To monitor animal health and assess any adverse effects of the probiotic treatments, 
we included a PBS control group, as well as a group administered EcN(J25) in the 
absence of SE. These control treatments enabled us to examine cecal score and bird 
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weight as indicators of overall health. All treatments showed no adverse effects, and bird 
weight remained nearly identical across all groups (Appendix B). In addition, we 
observed no visible changes between any of the groups in the morphology of the GI tract 
and the nature of the cecal contents. 
The probiotic does not colonize the intestinal tract as strongly as SE. The levels of 
the modified and unmodified probiotic were monitored throughout the course of the 
study. EcN and EcN(J25) passed through the intestines with a residence time of 3-5 days 
before counts dropped below the level of detection (Appendix B).  
Notably, none of the tested SE isolates exhibited microcin resistance following their 
passage to the cecum (Appendix B). 
3.4.3 Microbiome Analysis 
The poultry GI tract is developmentally very active in the early post-hatch period. 
Because intestinal health is critical to bird development, for years commercial poultry 
producers have used antibiotics to achieve and maintain GI stability and consistency 
within flocks70. Previous studies suggest that EcN enhances early GI tract maturation71, 
reduces shedding of enteric pathogens, and may improve body weight gain72. We 
performed a microbiome analysis on 258 ceca samples to ensure that our modification on 
Nissle did not adversely affect intestinal health.   
In Figure 3-4a, it is evident that the microbiota profiles in groups treated with the 
modified or unmodified EcN have no major differences. This implies that the microcin 
does not significantly alter the native gut microbial distribution, a challenge routinely 
encountered with standard antibiotic regimens 73. Consistent with previous work, we 
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observe clear temporal shifts in bacterial populations, with Clostridia spp. dominating the 
microflora 74. 
In accord with recent literature 75, SE significantly reduces microbial diversity 
across all infected groups. The untreated control birds and those administered solely 
EcN(J25) have markedly similar α-diversity profiles at day 14 (Figure 3-4b). The 
Figure 3-4. Modified probiotic has no discernible impact on microbial diversity  (a) 
Presence of microbial species in the bird’s microbiota in the ‘order’ taxonomic category. 
The ceca samples extracted from poults challenged with SE and treated with the modified 
probiotic (left) and unmodified probiotic (right) were averaged across both trials. The 
percent presence (×100) of the microbial species are shown for each collection point. (b) 
Alpha-diversity plot for Trial 1 at day 14 post-infection. UniFrac phylogenetic diversity 
was used as a criterion. 
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presence of the pathogen appears to have a more appreciable effect on diversity than the 
modified probiotic alone. In the SE-treatment models, EcN and EcN(J25) have similar 
effects further substantiating our conclusion. More detailed microbiota analysis is 
available in Appendix B. 
3.5 Discussion 
The presented technology reduced cecal SE carriage, taking advantage of the 
remarkable character of MccJ25, a naturally occurring AMP. AMPs are ancient host 
defense effector peptides, produced by organisms across all biological domains as part of 
the innate immune response against microbial challenge21. AMPs, for all their promise as 
alternatives to antibiotics, have failed in translational success, largely due to their high 
synthesis costs and rapid degradation in the body 21.  
The use of a probiotic delivery vector appears to overcome these economic and 
transport hurdles, enabling localized production of AMPs at the site of infection. EcN has 
demonstrated numerous health benefits in poultry 71,72 and is equipped with several 
fitness factors that allow it to persist in the intestinal environment, making it a prime 
candidate for this delivery platform 76.  
The brief period of colonization by EcN allows for a tunable treatment regime, 
enabling continuous administration through feed. The delivery of antimicrobial molecules 
may then be sustained for hours, or even days, localized at the site of infection.  
Several key questions concerning the delivery of peptides by bacteria remain. The 
most pressing ones are perhaps the ones related to the use of modified organisms. In 
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particular, the levels of release to the environment and the rate of DNA transfer of 
engineered components to other microbiota species have not been studied. There are 
ways to mitigate these risks, including suicide genes that will destroy the cells outside 
host GI tracts. This study's favorable proof-of-concept results suggest that larger 
programs that focus on the safety of antibiotic probiotics are warranted.  
From a practical viewpoint, a critical question is the influence of numerous 
alternative dosing regimens on SE carriage, bird health, and host microflora. A single, 
1ml inoculum proved sufficient to alter the trajectory of SE carriage and expedite 
shedding. Continuous administration by incorporation in the water or feed may have the 
potential of rapidly clearing SE in pre-harvest poultry.  
There are multiple engineering choices impacting the performance characteristics of 
antibiotic probiotics, including the choice of the bacterial strain and its colonization 
profile, the antimicrobial peptides, the expression strength, and the secretion pathways, to 
name a few. Optimizing the efficacy of antibiotic probiotics and determining the best 
dosing regimen may be best addressed through a combination of carefully designed field 
studies and smaller scale animal experiments. 
Finally, we note that the described strategy does not follow the traditional drug 
discovery and delivery process. Instead of identifying new therapeutic targets in 
pathogenic bacteria and developing new classes of drug molecules, probiotic bacteria can 
be recruited in the fight against pathogens. With available libraries of organisms, AMPs, 
and vectors for peptide production and secretion, this technology may be developed for 
numerous GI tract pathogens in a variety of hosts.  Fine-tuning antibiotic probiotic 
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systems may offer an alternative to antibiotics used in agriculture for pathogen reduction. 
This strategy can also potentially offer sorely needed solutions in the growing fight 
against antibiotic-resistant strains that infect and sicken humans. 
3.6. Materials and Methods 
3.6.1 Bacterial strains and plasmid construction 
The Pon promoter and the ProTeOn activator protein were synthesized by GENEART in 
a pMS expression vector that contains a ColE1 origin of replication and a Spectinomycin 
selection marker. Using standard molecular biology techniques, the mcjABCD operon 
was PCR amplified from the PJP3 vector (donated by J. Link, Chemical and Biological 
Engineering, Princeton University) and cloned into the pMS plasmid between the EcorI 
and SacI restriction sites. The final construct, pBF25, is illustrated in Supplemental 
Figure 1. pBF25 was transformed into EcN by electroporation for characterization 
(EcN(J25)). 
3.6.2 Zone of Inhibition Activity Assay 
EcN(J25) was cultured in Luria-Bertani (LB) media at 37°C with agitation at 225rpm. 
1ml of duplicate overnight cultures were transferred to a 2ml microcentrifuge tube and 
centrifuged for 3min @ 2.5rcf and the pellet was washed with 0.5ml of 1x PBS. At 
t=0hrs, the washed EcN(J25) was inoculated in 2ml of fresh LB to an OD of 0.05 in 5 
sterile culture tubes, allowing one tube per time point. At each point (0, 2, 5, 10, and 
20hrs) post-inoculation, 1.5mls of culture supernatant was collected from the respective 
tube and centrifuged for 1min at 15.8rcf. The supernatant was sterile filtered and stored at 
4°C. OD600 was measured at each time point. 
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M9 minimal agar plates (15g/L) were overlaid with 10ml of soft M9 agar (6.5g/L) 
containing 107 CFU of SE. The supernatant was serially diluted in two-fold steps and 
10μl of each dilution was spotted on the SE-agar plates. The reciprocal of the last dilution 
with a visible halo was taken as the activity units of MccJ25.   
3.6.3 In vitro supernatant activity assay 
Cultures of EcN(J25) and unmodified EcN were grown in LB and the supernatant was 
collected at 16hrs. Exponential phase SE was diluted to 103 CFU/ml and transferred to a 
96-well plate. Microcin-rich supernatant from EcN(J25) was applied to the SE at varying 
volume concentrations (0, 0.5, and 1%). The wells were blanked with spent media from 
the unmodified Nissle supernatant to obtain a final volume of 340 μl/well. The growth 
assays were obtained by shaking the plate at 37°C and taking OD600 measurements 
every 15 mins in a BioTek Synergy H1 microplate reader.  
3.6.4 Bacterial challenge/treatment of turkey poults 
All experiments were performed in accordance with relevant guidelines and regulations. 
This project was approved by the Institutional Biosafety Committee and by the 
Institutional Animal Care and Use Committee (IACUC) at the University of Minnesota. 
Day-of-hatch Hybrid Converter Breed Tom poults, free of vaccinations, were transported 
from a commercial hatchery. Birds were randomly transferred to isolator units with 
incandescent lighting, crinoline flooring, and ad libitum access to antibiotic and 
probiotic-free food and water. Three birds were taken to the University of Minnesota 
Veterinary Diagnostic lab prior to each trial to confirm they were Salmonella-free. The 
remaining birds were left in the units for a 3-day acclimation period following transport. 
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3.6.5 Bacterial Challenge Strains 
The SE and EcN challenge strains were both made resistant to antibiotics prior to 
inoculation so they could be recovered from the intestinal tract of the birds for 
enumeration. SE and EcN were both made resistant to 100μg/ml Rifampicin for this 
antibiotic concentration proved effective in limiting bacterial background from the poults. 
To differentiate the challenge strains, SE was additionally made resistant to 30μg/ml 
Nalidixic acid and EcN to 100μg/ml Streptomycin. On days 1 and 2 post-hatch of both 
trials, fecal samples were collected from each isolator unit and resuspended in PBS to 
make a final 10x dilution. The fecal samples were plated on the respective antibiotic agar 
plates to ensure there was no background bacterial growth in any of the units. Bacterial 
resistance was achieved using a ramping up and repeated exposure protocol77. 
3.6.6 Animal trial 1 
On day 0 (4-days post-hatch), 140 birds were randomly selected to make 5 groups of 28 
birds, with one group for each treatment ((5 birds per treatment per time point x 5 time 
points) + 3 extra birds per treatment to account for potential early losses). The birds were 
randomized at this stage to mitigate any early microbiome diversification that may have 
occurred during the acclimation period. Each group of 28 birds was placed into one of 
five isolator units and each unit underwent a different experimental treatment. The 5 
treatment groups evaluated in this study were: (1) SE-control, (2) SE + EcN(J25), (3) SE 
+ EcN, (4) EcN(J25)-control, and (5) PBS-control. 
On day 0, groups 1, 2, and 3 were orally inoculated with 108 CFU SE. Groups 4 and 5 
were inoculated with 1ml of 1x PBS. The birds were monitored for any signs of distress 
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for 2 hours post-challenge. On the following day the birds were inoculated in the same 
fashion with 1ml of their respective treatments, groups 1 and 5 with PBS, groups 2 and 4 
with 108 CFU EcN(J25), and group 3 with 108 CFU EcN. All bacterial treatments were 
suspended in 1ml PBS.  
On days 2, 4, 7, 10, and 14, five birds from each isolator unit were euthanized, weighed, 
and necropsied. We note that we added 3 surplus birds per unit to account for natural bird 
losses that are common in the first few days following hatch. At the final time point any 
remaining birds also were necropsied and data were collected. 
3.6.7 Animal trial 2  
Similar to trial 1, on day 0, birds were randomized from the isolator units they stayed in 
during their adjustment period to make 4 new groups of 38 birds. In this study, we used 
two isolator units per treatment, with 19 birds per unit. The 4 treatment groups in this 
study were: (1) SE control, (2) SE + EcN(J25), (3) SE + EcN, and (4) SE + .15mg 
ENR/(kg of bird weight). 
On day 0, all 4 groups were orally inoculated with of 108 CFU SE. On day 1, groups 1-4 
were treated with 1ml PBS, 108 CFU EcN(J25), 108 CFU EcN, and 1.5mg of ENR, 
respectively. On days 2, 4, 7, 10, and 14, 3-4 birds per unit (6-8 birds per treatment) were 
euthanized, weighed, and necropsied from each unit. At the final time point, any 
remaining birds were also necropsied and data were collected for all birds. 
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3.6.8 Enumeration of Salmonella and Nissle in cecal contents 
On post-inoculation days 2, 4, 7, 10, and 14, birds were randomly selected and 
euthanized from each isolator unit. Body weight was recorded and both ceca pouches 
were extracted. Ceca samples were weighed and transferred to sterile 7ml Precellys tubes 
(Bertin Corp) containing ten 2.8mm zirconium oxide (Bertin Corp) beads. Each sample 
tube was processed by adding 2ml PBS and using a Minilys® homogenizer for 15s at low 
speed. 
The homogenate for each sample was serially diluted in 10x increments and plated on 
selective media for SE and EcN enumeration. The plates were incubated overnight at 
37°C and then the colonies were counted.  
3.6.9 Statistical analysis of cecal counts 
CFU/g cecal tissue was determined for both SE and EcN from each bird at each time 
point. The data were log10 transformed and all data points with an enumerated CFU 
below the limit of detection were given a value of 0.5 CFU/g ceca. Extended discussion 
of the normality testing is discussed in Appendix B.  
Trials 1 and 2 were analyzed separately via ANOVA. In both trials, the ‘Treatment’ and 
‘Day’ were described as categorical variables, as well as, their interactions to account for 
different time-dependent responses. 
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Given these results, the null hypothesis that all treatments had the same effect was 
rejected. Therefore, pairwise post-hoc analysis was done between all treatments across all 
times using the Tukey-Kramer method (with) the computed confidence intervals (CI) of 
the differences of the transformed data. 
 
 
Table 3-1. ANOVA results for Trial 1 and Trial 2 
 
Table 3-2. . Pairwise analysis for Trial 1 treatments 
 
Table 3-3. Pairwise analysis for Trial 2 treatments  
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3.6.9 Microbiome Extraction and Analysis 
DNA was extracted from ceca samples using the MoBio Powersoil kit (Mo Bio Labs). 
Sequencing of the samples was performed at the University of Minnesota Genomics 
Center using Illumina MiSeq paired-end 2x300 bp technology of the V4 region of the 
16S rRNA. The pair reads were assembled using PandaSeq 782. The quality threshold for 
PandaSeq was set at 0.9. After the assembly, sequences were trimmed and converted 
from fastq to fasta format. ChimeraSlayer’s USEARCH 6.1 method 79,80 was used to 
remove potential chimeras. For the operational taxonomic unit (OTU) picking, QIIME’s 
80,81 open reference method was employed. For the closed-reference OTU picking, the 
Greengenes library 82 was employed through QIIME. For the unclassified sequences, de 
novo Uclust OTU picking 79 was used. QIIME was also used for the alpha diversity 
analysis using UniFrac 37. 
 3.6.10 Vertebrate Animal Experiments 
The University of Minnesota Institutional Animal Care and Use Committee has reviewed 
and approved protocol 1409-31793A involving all live vertebrate animals described 
herein, ensuring compliance with federal regulations, inspecting animal facilities and 
laboratories and overseeing training and educational programs. 
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Chapter 4 Engineered Probiotics to Target Multidrug-Resistant E. 
coli 
 
4.1 A Rising Superbug: E. coli Sequence Type ST131 
E. coli inhabit the intestines of human and animals making up a large portion of 
the facultative anaerobic intestinal population84. Although most E. coli are commensal 
inhabitants of the microbiota, there are several pathogenic strains of E. coli that can cause 
a variety of infections within their hosts. Based on the location of infection and type of 
resulting disease, the pathogenic variants are largely classified as either intestinal 
(InPEC) or extraintestinal pathogenic E. coli (ExPEC). InPEC strains tend to cause 
diarrheal diseases, while ExPEC strains cause infections at a variety of locations outside 
of the intestinal tract. ExPEC E. coli are the major cause of bacteremia and meningitis in 
neonates, and are responsible for 80% of urinary tract infections (UTIs)85. It is estimated 
that ExPEC E. coli cause 50% of hospital-acquired and 70-95% of community-acquired 
UTIs86. 
The treatment of pathogenic E. coli infections is complicated by their increasing 
spectrum of antibiotic resistance. Resistance to fluoroquinolones and trimethoprim-
sulfamethoxazole limit outpatient treatments while extended-spectrum cephalosporin 
resistance complicates treatment options in the hospital. Extended-spectrum 
cephalosporin resistance typically arises from bacteria harboring extended-spectrum β-
lactamases (ESBLs). ESBLs are enzymes that enable bacteria to hydrolyze β-lactam 
antibiotics, including penicillins, cephalosporins, and the monobactam aztreonam. This 
leaves only last resort antimicrobial therapies such as carbapenems87. 
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Most ESBL-associated E. coli infections are due to a recently emerged and 
globally disseminated ExPEC clone, ST13188. This previously unidentified clone was 
first reported in 2008 as having been found among ESBL-producing E. coli isolates from 
nine countries across 3 continents. Since then, ST131 has risen to dominance across the 
globe, with studies suggesting that the pandemic emergence of ST131 took place over 
less than 10 years89.  Surveys indicate that ST131 accounts for 10-27% of the total 
clinical E. coli population in several locations and between 52 and 67% of all ESBL-
producing or fluoroquinolone resistant E. coli88. 
Recent studies using whole genome sequencing have investigated the population 
structure of ST131. As shown in Figure 4-1, ST131 has several important sublingeages; 
notably the H30 subclones which contain the H30S, H30R, and H30Rx groups. The H30 
subclones are defined by the presence of a specific fimbrial adhesion allele, fimH30. 
Studies suggest that the expansion of ST131 in the U.S. has been driven primarily by the 
H30 group.  
Figure 4-1. ST131 genetic groups and acquisition of drug-resistance changes 
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Within H30, H30R branched off from H30S due to the acquisition of 
fluoroquinolone resistance, arising from mutations in the gyrA and parC genes. H30R 
strains constitute an estimated 58% of the total ST131 isolates86,90. The H30R strains 
contain further fine structure where the H30Rx subclones contain the same FQ resistance-
conferring mutations as does H30R1, but are also associated with ESBL production, 
typically of CTX-M-1590. The expansions of H30R and H30Rx reportedly began around 
25 years ago, when fluoroquinolones and extended-spectrum cephalosporins were first 
introduced for widespread clinical use90.  
ST131 infections manifest primarily as UTIs, most of which originate from 
intestinal colonizers86. In this work, we teamed up with Dr. James Johnson of the 
Veterans Affairs Medical Center to determine if engineered probiotics could be used to 
reduce the intestinal colonization of ST131 in carriers. Dr. Johnson has extensive 
experience in studying the epidemiology and resistance patterns of ST131. In this aim, 
we focused on an ST131 H30Rx isolate, JJ1886, which was recovered from a patient with 
fatal urosepsis. Dr. Johnson was part of a team that reported the whole genome sequence 
of this isolate91. 
In this work, we screened AMPs for activity against JJ1886, engineered EcN to 
elicit antibiotic activity against the isolate, and began to study the resistance mechanisms 
of JJ1886 to the AMP, Microcin C7 (Mcc7). 
4.2 Microcin C7: A Trojan Horse Antimicrobial Peptide 
Microcin C7 (Mcc7), the smallest microcin known, is a 21bp gene produced by E. 
coli isolates that harbor a plasmid-borne synthesis and immunity cassette containing the 
mccABCDEF gene cluster92. Mcc7 undergoes extensive post-translational modifications 
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during its biosynthesis, leading to a potent peptide antibiotic that inhibits aspartyl-tRNA 
synthetases (AspRS)93.  
Amino-acyl tRNA synthetases (aaRSs) catalyze the attachment of amino acids to 
cognate tRNAs, which are then transferred to growing peptide chains. aaRSs are 
promising targets for antimicrobial agents because they are critical for translating the 
genetic code94. Mcc7 structurally mimics an aspartyl adenylate, the native binder of 
AspRS, but exists in a nonhydrolysable form. Mcc7 thus binds to AspRS and essentially 
clogs the machinery, preventing further protein synthesis94.  
Mature Mcc7, which in this context refers to the form that is exported from the 
host cell but not yet internalized by the target, consists of a MRTGDAD heptapeptide 
with a covalently attached C-terminal adenosine monophosphate, a propylamine group 
attached to the phosphate, and an N-terminal formylated methionine (Figure 4-2).  
Mcc7 is imported into sensitive cells via the inner membrane transporter, 
YejABEF (YejF), which recognizes the leading hexapeptide portion of Mcc7. The 
biological function of YejF is not yet understood, but it presumably plays a role in the 
transport of oligopeptides, particularly those containing an N-terminal formyl-
Figure 4-2. Mature (unprocessed) Mcc7 and Processed (Toxic) Mcc7. Adapted from 
Novikova et al. The Journal of Biological Chemistry. 2010; 285(17). 
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methionine92. Upon cell entry, the N-terminal formyl methionine is removed by peptide 
deformylase and then the peptide portion is cleaved sequentially by intracellular 
peptidases. This cleavage process releases the toxic aspartyl adenylate analogue into the 
target cell (Figure 4-2). Mcc7 is therefore actively transported into sensitive cells, where 
the portion for facilitated transport is subsequently removed to release the entry-incapable 
peptide antibiotic, making Mcc7 a bona fide ‘Trojan Horse’ inhibitor. Other naturally 
occurring aminoacyl adenylate-based antibiotics use similar strategies, including the 
leucyl-tRNA synthetase inhibitor, agrocin 84, and the seryl-tRNA synthetase inhibitor, 
albomycin92. 
Despite the small size of Mcc7, five enzymes spanning a ~6kb region are required 
for the processing, transport, and host immunity of the peptide. The keys steps in this 
sequence, from the host cell's processing of Mcc7 to target-cell inhibition, are depicted in 
Figure 4-395.  
The biosynthetic gene cluster governing Mcc7 production contains two opposing 
operons. The first dictates the expression of mccABCDE while mccF is transcribed 
independently in the reverse direction. The promoter upstream of mccA, Pmcc, is a CAP 
(catabolite activator protein)-dependent promoter, which is activated in the decelerating 
phase of growth or in nutrient-limiting environments.  
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The biosynthesis of Mcc7 begins with the product of mccA, a heptapeptide 
consisting of MRTGNAN and is the initial precursor of Mcc7. This peptide is converted 
into a biologically active intermediary form by an adenylation reaction catalyzed by the 
MccB enzyme. MccD and MccE then jointly contribute to modifying the MccB-catalyzed 
product with propylamine, increasing the biological activity of the peptide by ~10 fold. 
This mature Mcc7, and some intermediary forms, are exported by a major facilitator 
superfamily efflux pump encoded by mccC93. 
Unprocessed Mcc7 can be processed into the toxic form by the intrinsic 
peptidases of the producing bacterial cell. Such host cell toxicity is avoided because the 
Mcc7 gene cluster includes built-in methods to detoxify the peptide. Three gene products 
Figure 4-3. The mechanism of action of Mcc7.  Reproduced with permission from 
Piskunova et al. Molecular Microbiology, 104.  
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contribute: MccE, MccF, and MccC. MccE is an acetyltransferase that acetylates 
processed Mcc7, thereby detoxifing it96. MccF is a serine peptidase that cleaves the 
isopeptide bond in Mcc7 that connects the AMP moiety. MccC is capable of exporting 
both intracellularly produced and externally acquired Mcc792. 
4.3 Development of a Mcc7-Producing Probiotic 
4.3.1 Analysis of the Mcc7 Promoter 
Mcc7 was donated to the Kaznessis lab by Dr. Konstantin Severinov of the 
Rutger’s Wacksman Institute. In this study, we used the donated pp70 plasmid, which is 
about 9kb and contains the native Mcc7 gene cluster in a pBR322-based vector with an 
Ampicillin resistance marker (Figure 4-4).  
In my initial efforts to improve Mcc7 titers from E. coli containing pp70, I 
focused on swapping out the native Mcc7 promoter, Pmcc, with staple promoters 
developed in the Kaznessis lab such as ProTeOn+ and TTL97. In previous work, these 
promoters had led to successful increases in secreted peptide titers from AMP-producing 
Figure 4-4. Plasmid map of pp70 
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E. coli. However, here all these constructs failed to compete with the native genetic 
operon of Mcc7 leading to overall reductions in antimicrobial activity. This led me to 
characterize the Pmcc promoter to better understand its strength and expression profiles, 
thereby clarifying system behavior.  
The Pmcc promoter is CAP-activated and exhibits growth-phase-dependent 
regulation92. In a previous study, Pmcc was shown to activate expression during the 
decelerating phase of cell growth, upon transition into stationary phase. Regulation of the 
promoter depends on a complex interplay of at least four global regulators of 
transcription including the σs-subunit of RNA polymerase and the CRP, H-NS, and LRP 
proteins. It is hypothesized that the H-NS and LRP regulators are involved in the 
repression of Pmcc expression in exponential phase65. 
Here, the Pmcc promoter was isolated from the pp70 plasmid and placed 
upstream of GFPmut3 (GFP). Promoter strength was compared to the native MccV 
(Pcvi), MccJ25 (Pmcja), and ProTeOn+ promoters in parallel with Pmcc. The Pmcc 
promoter sequence is show in Figure 4-5. The sequences of the other AMP promoter 
regions tested are available in Appendix C. As shown in Figure 4-6, although Pmcc was 
activated more strongly at later stages of growth, it consistently exhibited higher 
Figure 4-5. Sequence of the Pmcc promoter.  The Pmcc promoter was isolated from pp70 
and placed upstream of GFP. Key features of this sequence, including the CRP binding 
site, -10 element, RBS, and start of GFP, are denoted. 
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expression levels than any of the tested promoters, including ProTeOn+. This explains 
the decrease in activity we had observed with our systems when different promoters were 
used in place of Pmcc. Therefore, in subsequent work we used Pmcc for gene expression.  
 All the AMP promoters showed steep activation during the later stages of growth. 
OXB20 was included as a control for the accumulation rate that a constitutive promoter 
exhibits upon entering stationary phase. Between 11 and 19 hours, the ProTeOn+, 
Figure 4-6. Expression profiles of native AMP promoters, OXB20, and ProTeOn+.  
ProTeOn+, OXB20, and the native MccV (Pcvi), MccJ25 (PmcjA), and Mcc7 (Pmcc) 
promoters were placed upstream of GFP. MC1061 was used as the host strain for all 
constructs tested. In a kinetic spectrophometric assay, OD600 and fluorescence 
readings were measured at 30-min intervals. Fluorescence was plotted as a function of 
OD600. Error bars represent standard error of four replicates. 
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OXB20, Pcvi, Pmcja, and Pmcc promoters increase their fluorescence by 7.5, 6.5, 12.5, 
22, and 11.5-fold, respectively. 
 4.3.2 In Vitro activity of Mcc7 producing E. coli 
We screened the activity of several microcins, including Microcin V, Microcin L, 
Microcin N, and Microcin J25, against a panel of ST131 isolates provided by Dr. 
Johnson. Binary results of these screens are shown in Table 4-1. This screen leaves open 
the potential for future engineering efforts against these isolates. Results of a zone-of-
inhibition assay showing the inhibitory activity of Microcin J25 and Microcin V against 
ST131 strains JJ1901 and MVAST020 are available in Appendix C. However, Mcc7 had 
significantly more potent activity against the target of interest, JJ1886, than did the other 
microcins.  
With Pmcc being the strongest constitutive promoter tested, for subsequent assays 
we used the unmodified pp70 plasmid containing the native Mcc7 operon. For 
characterization, we transformed pp70 into EcN and used liquid supernatant assays to 
measure the inhibitory effect on the growth kinetics of JJ1886. The Mcc7-producing 
Table 4-1. Binary Screening Results of Microcins J25, V, L, and N for activity against 
ST131 isolates  
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Nissle derivative (EcN(C7)) was grown in LB media for 13 hours, at which time the 
Mcc7-rich supernatant was collected and applied to seed cultures of JJ1886 in different 
volume fractions in a 96-well plate. We screened serial two-fold dilutions, from 40% to 
0.625%, of the studied Mcc7-containing supernatants (e.g., Figure 4-7). Treatment with 
40% Mcc7 supernatant suppressed growth of JJ1886 for ~9 hours, while treatment with 
0.625% suppressed growth for 7 hours. In this assay, we did not dilute sufficiently to 
capture the MIC. However, based on the range of volume fractions tested, this 
peptide/pathogen combination appears to be the most potent system developed in the 
Kaznessis lab thus far, outcompeting MccJ25 vs SE. 
Figure 4-7. In vitro activity of Mcc7 against JJ1886. Supernatant was collected from 
EcN(C7) at 13hrs and applied in different volume fractions ranging from 0.625% to 40% 
to JJ1886 (OD~0.01). A kinetic spectrophometeric assay was run for 12hrs and OD600 
readings were measured periodically. The error bars represent standard error of 3 
replicates. 
 
 
 
64 
 
The susceptibility of JJ1886 to Mcc7-containing supernatant was tested in 
different media conditions to determine if any shifts occurred when nutrient composition 
was altered. It is hypothesized that many transporters, possibly YejF, are upregulated 
when nutrients are scarce, increasing the amount of entry points for AMPs. JJ1886 
growth was tested in the presence of Mcc7-containing supernatant during growth in rich 
(LB) and limiting (M9) media  
As shown in Figure 4-8, the susceptibility of JJ1886 shifts to higher inhibitory 
levels upon treatment in M9 media exhibiting a lower MIC. In M9 media, with all Mcc7 
treatments tested, the growth curves of JJ1886 were superimposed with growth only 
Figure 4-8. JJ1886 susceptibility to Mcc7 during growth in different nutrient conditions. 
Mcc7 supernatant was collected from MC1061 cells containing pp70 at 16hrs. The 
supernatant was applied to JJ1886 (OD~0.001) at different volume fractions ranging from 
10-2.5%. JJ1886 growth was monitored via OD600 upon treatment in LB and M9 media. 
The error bars are the standard error of 3 replicates. 
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beginning at 12hrs. In contrast, the LB group displayed growth curves that begin less than 
10hrs after treatment with 2.5 and 5% supernatant. These shifts indicate that JJ1886 is 
likely more susceptible to Mcc7 when nutrients are scarce. 
4.4 Mechanism of Resistance in JJ1886 
Resistance is an inevitable side effect of antimicrobial therapies. Despite the 
potency of Mcc7 against JJ1886, there remains a resistant subset within the population 
that is unaffected by the toxic peptide. We chose to explore this resistant subset to gain 
better insight into the mechanisms of resistance. Understanding the peptide evasion 
process could aid in the development of combination therapies to create more effective 
treatments.  
Mcc7 resistance could arise due to several distinct types of mutations. For 
example, mutations could affect the intracellular target (AspRS), the peptidases of the 
sensitive cells that process Mcc7 into its toxic form, or the import or export mechanisms 
of Mcc7 from the target cell. Mutations in AspRS are likely difficult for cells to acquire 
and maintain because AspRS is an essential enzyme; mutations that confer Mcc7 
immunity could alter binding with the native substrate and thus affect cell viability. 
Mutations in the peptidases would also be challenging for cells to achieve because there 
are many redundant and non-specific peptidases in the E. coli genome98. This led us to 
focus on the import/export mechanisms of Mcc7 for their role in Mcc7 resistance. 
In a previous study, the YejF transporter was determined to be essential for Mcc7 
sensitivity and deletion of any of the four genes of the operon is sufficient for 
resistance98. We hypothesized that down-regulation of this transporter would be the 
resistance mechanism of the resistant subpopulation of JJ1886. If this transporter were 
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down-regulated on some targets, the peptide could have less opportunities to enter the 
cells and exert its antibiotic effect, yielding a resistant phenotype. 
The YejF transporter is produced by four genes that are transcribed as a single 
operon, yejABEF. yejA encodes a putative periplasmic binding protein, yejB and yejE 
encode for putative permease components, and yejF encodes for the ATPase 
component99.   
We determined the frequency of resistance of JJ1886 to Mcc7 to be 1 x 10-6 CFU. 
We then isolated spontaneous mutants of JJ1886 that had stable a resistance pattern. We 
classified mutants as ‘stably resistant’ if they grew in rich media without selection 
pressure and exhibited a similar survival rate on LB agar plates in the presence and 
absence of Mcc7.  
 We then used Real-Time Quantitative Reverse Transcription PCR (qRT-PCR) to 
assess yejF expression by wild-type JJ1886 and its Mcc7-resistant mutants during 
exponential-phase growth in LB media.  Preliminary results are shown in Figure 4-9. 
Reevaluation of these preliminary results, with the JJ1886 gapA and hcat housekeeping 
genes used as controls, is ongoing. 
 In these preliminary results, six out of seven resistant mutants had significant 
downregulation of yejF compared to the susceptible group. The transcript levels of yejF 
show between a 3 and 6x reduction compared to the susceptible group. These results are 
consistent with our hypothesis that JJ1886 resistance involved down-regulation of the 
YejF transporter. 
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 The YejF transporter has been found to contribute to the virulence of Salmonella 
Typhimurium and Brucella melitensis. Salmonella and Brucella stains with mutations or 
deletions in the YejF transporter showed increased susceptibility to AMPs and peptide 
antibiotics including, protamine, melittin, polymyxin B, human beta defensins (HBD)-1 
and (HBD)-2, and restricted invasion of and replication in macrophages. In mouse 
models, as compared to the parental strains Brucella yejF mutants showed more rapid 
clearance rate from the spleen of infected mice and Salmonella yejF mutants 
demonstrated decreased virulence when administered intragastrically 99,100. If the Mcc7-
resistant population of JJ1886 does down-regulate YejF, this subset might be inherently 
less virulent and may not be capable of causing reinfection if left behind following 
 
Figure 4-9. yejF down-regulation in Mcc7-resistant JJ1886 mutants. yejF transcript 
levels were measured using qRT-PCR. Six out of seven Mcc7-resistant mutants exhibit 
significantly lower yejF transcript expression compared to the susceptible population. 
Each isolated was tested in biological replicates with technical duplicates. The fold 
change and error was calculated using the ΔCt method. *p<.05, **p<.01. 
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EcN(C7) treatment. It is also possible to follow EcN(C7) treatment with peptide 
antibiotics such as polymyxin B to eradicate this resistant population in vivo. 
4.5 Future Directions 
4.5.1 Test EcN(C7) in mouse decolonization models  
Dr. Johnson has established colonization models of ST131 E. coli in the GI tract 
of mice. In these models, colonization is established and maintained using Streptomycin 
selection and Streptomycin-resistant test strains. Using these models, we will test our 
engineered Nissle, EcN(C7), as a decolonization measure. For this, we will challenge 
mice with JJ1886 via oral gavage and treat them with EcN, EcN(C7), and PBS in the 
drinking water. EcN(C7) has been made resistant to Rifampicin (100ng/µl) and 
Streptomycin (100ng/µl), and JJ1886 is intrinsically resistant to Ciprofloxacin (10ng/µl) 
and has been made resistant to Streptomycin (100ng/µl), which enables us to get colony 
counts of bacteria in the GI tract via selective plating. 
4.5.2 Peptide Engineering of Mcc7  
A possible future direction in this project would be to apply rationale peptide 
engineering techniques to broaden the spectrum of activity of Mcc7. Mature Mcc7 is 
capable of functioning through a ‘Trojan Horse’ mechanism due to its modular structure, 
whereby the non-hydrolyzable apartyl adenylate is attached to a hexapeptide carrier that 
facilitates transport into sensitive cells upon recognition by YejF.  
It could be possible to capitalize on these modular components to either (1) attach 
other toxic molecules to the hexapeptide carrier or (2) change the hexapeptide carrier to 
allow the transport of Mcc7 into cells through alternate entry point. Previous studies have 
demonstrated that substitutions in the seventh amino acid of MccA prevent Mcc7 
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production, likely due to preventing interactions with the enzymes involved in post-
translational modifications101. However, chemically synthesized Mcc7-like compounds 
can exhibit antibiotic activity after cellular uptake via the Mcc7 import mechanism. 
Vijver et al. linked aminoacyl-sulfamoyl adenosines, which are nanomolar inhibitors of 
their cognate aspartyl-tRNA synthetases (aaRS), to the hexapeptide carrier. Synthetic 
compounds such as these could specifically target the aaRSs for which they were 
designed94.  
This study by Vijver et al. shows promise in exploiting the modular nature of 
Mcc7 to enable the carriage of other toxic molecules. However, although such an 
approach may be possible, we suspect that the extensive post-translational modifications 
that occur during Mcc7 processing will make it challenging to identify C’ terminal 
analogues that are compatible with the processing enzymes required for production from 
engineered probiotics. Accordingly, this approach may be best suited for chemical 
synthesis applications. Mcc7 exhibits broad activity on AspRSs from a wide variety of 
organisms; resistance is attributed largely to restricted cellular uptake. We propose 
focusing on modifying the hexapeptide carrier to target alternative importers. Such 
synthetic Mcc7 compounds could be tuned to target specific pathogens that lack YejF, or 
administered as part of a cocktail for broader activity. The ability to expand the activity 
spectrum of the Mcc7 platform through either of these mechanisms would greatly 
increases its value and potential as a novel antibiotic, with or without the use of 
engineered probiotics.  
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4.6 Materials and Methods  
4.6.1 Promoter assays with GFP  
The Pcvi, Pmcja, and Pmcc promoters were synthesized by IDT and inserted into 
pBFmut3 using HIFI assembly (NEB). The promoter sequences including the HIFI 
assembly homology sites are available in Appendix C. The plasmids developed –
pBFG10, pBFG11, and pBFG12 – were transformed into MC1061 via electroporation for 
characterization, leading to strains BFG10, BFG11, and BFG12, respectively.  
Strains BFG10, BFG11, BFG12, MC1061(psF_OXB20Mut3) (positive control)), 
MC1061 (negative control), and MC1061(pBFmut3) were cultured for 12hrs in 2ml LB, 
supplemented with antibiotics when necessary (100ng/ul Spectinomycin or 50ng/ul 
Kanamycin). Overnight cultures were diluted in LB to OD~0.5. 5µl was then transferred 
to 5ml selective LB. 300µl of each dilute culture was transferred to a black-walled 96-
well plate in four replicates. Using a BioTek Synergy H1 microplate reader, the plate was 
maintained at 37C in double-orbital mode. Fluorescence intensity and OD600 were 
measured at 30 min intervals for 20hrs. Background fluorescence was corrected for by 
subtracting out the average background fluorescence of MC1061F at the respective 
OD600 values of the sample reading.  
4.6.2 Kinetic supernatant inhibition assays 
MC1061 or EcN containing pp70 were grown for 12-16hrs in antibiotic-free LB media. 
1.5ml of the overnight cultures were centrifuged for 3min at 2.5rcf and the supernatant 
was sterilized using a .22µm filter. The supernatant was two-fold serially diluted in spent 
MC1061 media. 180µl JJ1886, diluted to OD~0.001 in LB or M9 minimal media, was 
transferred to a 96-well plate and treated with 120µl of each serially diluted supernatant 
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treatment. In the BioTek Synergy H1 microplate reader, OD600 was measured at 20-30 
min intervals, while the plate was maintained at 37C in double-orbital mode. Each 
treatment was tested in 3 or 4 replicates.  
4.6.3 Isolation of JJ1886 mutants stably resistant to Mcc7. 
LB agar plates were supplemented with 20% Mcc7 supernatant collected from 
MC1061(pp70). 30µl of an overnight JJ1886 culture in LB media underwent 10x serial 
dilution in phosphate-buffered saline (PBS). 10µl of the serial dilutions were plated on 
LB plates with and without 20% Mcc7. Plates were incubated overnight at 37C and the 
colonies on LB +/- Mcc7 were counted. The frequency of resistance (FOR) was 
calculated as shown below: 
𝐹𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦 𝑜𝑓 𝑟𝑒𝑠𝑖𝑠𝑡𝑎𝑛𝑐𝑒 (𝐹𝑂𝑅) =  
𝐶𝐹𝑈
𝑚𝑙  𝑣𝑖𝑎𝑏𝑙𝑒 𝑜𝑛 20% 𝑀𝑐𝑐7 𝑝𝑙𝑎𝑡𝑒𝑠
𝐶𝐹𝑈
𝑚𝑙 𝑣𝑖𝑎𝑏𝑙𝑒 𝑜𝑛 𝐿𝐵 𝑝𝑙𝑎𝑡𝑒
 
 
Colonies that grew on Mcc7+ plates were cultured in LB media with no selective 
pressure and the above protocol was repeated twice. Mutants were determined to be 
stably resistant if colony counts on plates with and without Mcc7 were constant. 
4.6.4 qRT-PCR analysis of yejABEF  
Triplicate colonies of both JJ1886-S (i.e., Mcc7-susceptible) and each JJ1886-R (i.e., 
Mcc7-resistant) mutant were inoculated from LB agar plates into LB media without 
selection pressure and incubated overnight at 37C with 225rpm. The overnight cultures of 
each replicate were diluted to OD~0.1 in LB and incubated for an additional 3hrs. In the 
preliminary study in this thesis, the samples were submitted to the University of 
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Minnesota Genomics Center for RNA extraction, cDNA preparation, and qRT-PCR of 
yejF. Each sample was tested with two technical replicates.   
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Chapter 5 Microcin V: Foundation for modular AMP-expression 
systems 
 
5.1 Introduction 
In our previous work, we demonstrated the potential and versatility of EcN as an 
AMP-delivery system. However, when using an engineered probiotic that produces only 
a single AMP, several challenges may arise throughout the course of treatment.  
For one, microcins tend to have very specific activity that is confined to a narrow 
subset of bacterial species13. This presents the issue that the pathogen underlying disease 
may need to be identified prior to administration of the engineered probiotic for the 
treatment to be effective. Identification of the causative agent typically requires a few 
days to a week which would delay treatment onset102. This is in contrast to many small 
molecule antibiotics which are broad-spectrum and can be administered with successful 
outcomes without knowing the precise species underlying the illness. 
There is also the issue we discussed previously, that within a bacterial population 
there typically exists a resistant subset that is immune to the activity of the peptide and 
can survive the AMP treatment. These resistant strains can persist in the gut environment, 
passing on their resistance genes to neighboring organisms. This makes future treatments 
more difficult and can give rise to new strains of resistant bacteria. 
To overcome these challenges, we have explored the possibility of developing 
engineered probiotics that can simultaneously produce multiple AMPs. The ability to 
deliver multiple peptides in parallel can enable the development of broader-spectrum 
probiotics that can elicit activity against a wider range of bacteria or they could be 
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engineered to express peptides that have orthogonal mechanisms of action against a 
single target to decrease the size of the resistant population. 
One of the major hurdles associated with peptide expression from probiotic 
organisms stems from secretion barriers. In many cases, AMPs are exported by dedicated 
secretion pathways or rely on extensive post-translational modifications prior to release. 
In this work, we focused on releasing multiple peptides from the well-studied Microcin V 
(MccV) secretion pathway.  
5.1.1 Heterologous Secretion of Antimicrobial Peptides 
Previous work has explored the possibility of releasing AMPs from alternate 
secretion pathways and in heterologous hosts with promising results. In one notable 
study, Borrero et al. were seeking methods to produce Enterococcal AMPs, or enterocins, 
from Lactococcus lactis (L.lactis) due to concerns over Enteroccocus associated 
infections. To do this, they replaced the native signal peptides of two enterocins, 
Enterocin P (EntP) and Hiracin JM79 (HirJM79), to the signal peptide of Usp45. Usp45 
is a Lactococcal protein released by the Sec-dependent pathway, a conserved export 
system that transports unfolded proteins across the cell membrane through a pore formed 
by the SecYEG complex. Usp45 is the major Sec-dependent protein secreted by L.lactis. 
Fusions of Usp45 to EntA and HirJM79 successfully enabled the production, secretion, 
and expression of these peptides in the extracellular space of the engineered L. lactis103.  
In a similar study, it was shown that divergicin A, a bacteriocin produced by 
Carnobacterium divergens LV13, could be exported through the pathways of leucocin A 
and lactococcin A by exchanging the leader peptide of divergicin A with those for 
leucocin A and lactotoccin A, respectively. In this study, it was found that expression of 
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divergicin A was maximized when the attached leader peptide was expressed in the host 
it was derived from104.  
Related to the study presented in this work, it was demonstrated that the MccV 
leader peptide (Vsp) could be used to transport divergicin A out of E.coli and L. 
gelidium104. In this work we expand upon this foundation in developing a modular 
expression cassette for the expression of multiple AMPs using MccV’s pathway. 
5.2 Genetic Organization of Microcin V 
The simplicity of Class IIa microcins, such as MccV, makes them an ideal model 
system for the development of polycistronic constructs. Class IIa microcins reside on 
gene clusters that only require four genes for peptide synthesis and export and their post-
translational modifications are limited to disulfide bonds. MccV, the focus of this study, 
was the first antibiotic substance reported to be produced by E.coli and is one of the best 
studied microcins to date. MccV acts on sensitive cells by targeting the Cir iron receptor 
and disrupting membrane potential of the target cell13. 
The genetic organization of the MccV operon is shown in Figure 5-1a. The MccV 
gene cluster is 4.2kb long and contains two converging operons. MccV is first produced 
as a precursor peptide encoded by cvaC. This 103-amino acid precursor contains an N-
terminal leader sequence, which is a common feature among secreted proteins, and is 
responsible for directing the precursor to its dedicated transport system (Figure 5-1b). cvi 
encodes for a self-immunity protein that protects the host cells from the toxic effect of 
MccV13. 
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The MccV export system is composed of three essential genes, cvaB, cvaA, and 
tolC. The ABC transporter, CvaB, and the accessory protein, CvaA, are plasmid-encoded 
genes expressed from the MccV operon105. TolC is a chromosomally expressed outer 
membrane protein which plays a fundamental role in many E. coli export systems. A 
schematic of the proposed organization of the full transporter is shown in Figure 5-1c.  
The leader peptide of CvaC contains a double glycine motif which is a conserved 
attribute of many secreted bacteriocins. The processing of the precursor peptide occurs 
concomitantly with export through the ABC transporter106. The transporter contains an N-
terminal cysteine protease domain which cleaves the leader peptide directly after the 
glycine motif. This occurs on the cytoplasmic side of the membrane during MccV export. 
  
Figure 5-1. Key elements of MccV development. (a) The native operon of MccV contains 
four plasmid borne genes. cvaC encodes for the microcin precursor, cvi encodes for the 
immunity gene, cvaA and cvaB encode for components of the ABC transporter. (b) cvaC 
contains an N-terminal leader peptide (underlined) which is cleaved during export to 
release the mature MccV. (c) Proposed schematic of the ABC transporters organization 
for MccV export. (Adapted from Duquesne et al. Nat. Prod. Rep., 2007, 24 with permission 
from The Royal Society of Chemistry.) 
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5.3 Results 
5.3.1 Development of pMPES 1.0 
The design, construction, and testing of pMPES 1.0 was carried out by myself 
along with Madeline McCue, Evelyn McChesney, and Kathryn Geldart. A manuscript 
detailing this work is available in MDPI Pharmaceuticals26, however in this dissertation I 
will focus on the portions of the project that were advanced primarily by my 
contributions with the goal of developing advanced engineered probiotics.  
In previous work, Professor Kolter’s group at Harvard University developed the 
plasmid, pHK22107. As shown in Figure 5-2, pHK22 harbors a 9.4kb subcloned region 
which contains all the genes required for MccV production and secretion in a pACYC184 
backbone. In our proof of concept studies, pMPES 1.0 was developed by mutating the 
start codon of the MccV structural gene (denoted as mCvaC) to abolish any activity 
produced by the peptide at this location (Figure 5-2). At an alternate site we inserted the 
ProTeOn+ promoter upstream of a multiple cloning site so we could easily add different 
Figure 5-2. Plasmid maps of pHK22 and pMPES 1.0 
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peptides with variable signal sequences to determine if they could be successfully 
exported by the MccV secretion pathway.  
5.3.2 Bacteriocins tested for secretion  
In this study we chose to attempt to export a wide variety of bacteriocins to 
determine the limits and potential of this system. We initially began with alternative E 
.coli class IIa microcins including Microcin L (MccL) and Microcin N (MccN), due to 
their similarity to MccV. We then expanded the screen to include class II enterocins, 
including EntA, HirJM79, Enterocin P (EntP), and Enterocin B (EntB).  
All of the peptides tested contained double glycine motifs in their native leader 
peptides, except for EntP and HirJM79, which are believed to be secreted by the Sec 
Figure 5-3. Sequence comparisons of bacteriocins exported from the MccV secretion 
pathway. The top table shows the percent identity and similarity of the leader peptide, 
processed peptide, and primary secretion genes of each bacteriocin studied to the 
corresponding feature in the MccV operon. The identity and similarity values were 
calculated using the EMBOSS Needle global sequence alignment program. The bottom 
figure shows an alignment of the signal peptides and first 10 amino acids for the mature 
peptide.*=fully conserved residues, :=high conservation (scoring >0.5 in the Gonnet 
PAM250 matrix);.=low conservation (scoring <0.5). (Reproduced from Pharmaceuticals.  
2016, 9(4), 60.) 
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protein translocation pathway. Figure 5-3 shows the percent identity and similarity of the 
leader peptides, processed peptides, and primary secretion genes. The secretion genes of 
EntB, HirJM79, and EntP were not included because they were either unknown (EntB) or 
belonged to the Sec pathway. The identity and similarity values were calculated using the 
EMBOSS Needle global sequence alignment program26.  
Additionally, the leader peptides and the first 10 amino acids of the mature 
peptides were aligned using the multiple sequence alignment program, Clustal Omega. 
Amino acid conservation scores are based on the Gonnet PAM250 substitution matrix. 
Residues scoring >0.5 are considered highly conserved in similarity26. = 
The peptide constructs tested and their corresponding results are displayed in 
Table 5-1. Although not the focus of this dissertation, we demonstrated we could export 
the majority of combinations tested. Vsp linked to MccV, MccN, EntA, HirJM9, EntA, 
EntP, and EntB could all be secreted through the MccV pathway with variable success. 
MccL and MccN were also expressed well from the MccV pathway when using their 
Table 5-1. Inhibitory activity of pMPES 1.0 producing bacteriocins. 
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native leader peptides, Lsp and Nsp, respectively. All of these constructs were tested in 
MC1061 cells. 
Previous work has focused on secreting two or three AMPs from a single bacterial 
delivery organism. However, the work presented in this section builds on this foundation 
demonstrating the ability to combinatorically swap leader peptides and develop AMP 
expression systems capable of producing a wide-variety of diverse peptides. 
5.3.3 Development of pMPES 3.0 
pMPES 1.0 served its purpose as a proof-of-concept tool for a modular peptide 
expression system. However, a major downfall of pMPES 1.0 was that it elicited poor 
peptide expression overall. In this work, we set out to improve and optimize pMPES 1.0 
to make it a more robust tool so it could feasibly be used for practical applications.  
The optimized pMPES vector, termed pMPES 3.0, is displayed in Figure 5-4. In 
constructing this vector, we made several key changes that led to improved peptide 
production. In pMPES 1.0, the entire MccV operon was contained in the vector 
Figure 5-4. Plasmid map of pMPES 3.0  
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backbone, including an extra ~4kb region of unnecessary sequence space. This region 
contained several hypothetical protein coding regions of unknown function. In pMPES 
3.0, we eliminated the unnecessary sequence space and confined the cloned region of the 
MccV operon to include only the four essential genes required for MccV production and 
secretion. We removed the downstream coding region for cvaC and cvi, which were 
mutated in pMPES 1.0, choosing to express these proteins only from the ProTeOn+ 
promoter upstream. Lastly we cloned this engineered operon into the pMS vector 
backbone which contains a Spectinomycin resistance marker and ColE1 origin of 
replication.  
To evaluate the strength of pMPES 3.0 vs 1.0 and quantify differences in their 
expression capacity, we expressed MccV from both vectors to measure relative 
concentrations and secretion output.  We measured the differences in MccV production 
from each system using a combination of kinetic supernatant and zone-of-inhibition 
activity assays with DH5αpro (DH5α) as the indicator strain.  
For the supernatant assays, we collected the supernatant from MC1061 cells 
producing MccV from both pMPES 3.0 and 1.0 after 16hrs of growth. We then applied 
this supernatant to DH5α in different volume fractions ranging from 40% to 0.625% and 
kinetically measured the growth profiles of DH5α. Using the growth curves collected 
from these assays, we were able to fit the data to Hill curves to examine shifts in the 
potency of the treatments. To generate these curves we used the Time to Rise (TTR) 
method explained in Section 5.4.4. The generated curves are shown in Figure 5-5. These 
curves shift to lower inhibitory concentrations of supernatant following treatment with 
pMPES 3.0 supernatant, indicating the presence of higher concentrations of MccV.  
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  In Figure 5-6, kinetic inhibition assays are shown where supernatant was collected 
from MC1061 cells producing MccV from pMPES 3.0 and 1.0. The supernatant was 
collected at 16hrs from both systems and DH5α growth is shown upon treatment with 
1.25 to 10% supernatant collected from each. There are clear shifts in the growth profiles 
of DH5α in the presence of pMPES 3.0’s supernatant indicating higher inhibitory 
concentrations. The activity, based on TTR calculations, is increased by 8x in pMPES 
Figure 5-5. Hill curve fitting of pMPES 1.0 and pMPES 3.0. .  The curve fits the TTR 
values of the indicator strain, DH5α, following treatment with serial dilutions of 
supernatant collected from MC1061 cells producing MccV from pMPES 1.0 and 3.0. The 
TTR was calculated as the average of three biological replicates. 
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3.0. Additional studies producing enterocins have shown that the MIC when producing 
these peptides is increased over 20x in pMPES 3.026. 
Figure 5-7. Zone-of-Inhibition assay of pMPES 1.0 and 3.0 vs DH5α. MC1061 cells 
producing MccV from pMPES 1.0 (P1) and 3.0 (P3) were spotted on an agar plate seeded 
with DH5α. 
Figure 5-6. Kinetic inhibition assay of DH5α in the presence of supernatant collected from 
pMPES 1.0 and 3.0 producing MccV.  DH5α growth was measured in the presence of 
different volume fractions of supernatant collected from MC1061 cells producing MccV 
from pMPES 1.0(left) and 3.0(right). 
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 A halo test shown in Figure 5-7, shows the relative size of halos produced from 
pMPES 1.0 (P1) and pMPES 3.0 (P3) against DH5α. We note that the radius of the halos 
is not linearly related to peptide concentration but should increase with r2, so a small 
change in halo size is a dramatic increase in peptide content. 
5.4 Secretion of peptides from EcN using MccH47 Export Machinery 
One of the reasons EcN is hypothesized to have powerful probiotic activity is due 
to its natural chromosomal carriage of two AMPs, Microcin M (MccM) and Microcin 
H47 (MccH47)13. MccH47 shares the same mode of secretion as MccV and their ABC 
export systems are almost identical. The two genes involved in MccH47 export, mchE 
and mchF, derived from EcN were found to be 98 and 99% identical to the cvaA and 
cvaB genes of the MccV operon108. In this work, we sought to determine if we could 
utilize the MccH47 machinery to export MccV from EcN. Being able to do this would 
enable us to secrete MccV, and potentially other peptides, without burdening the cells 
with the task of producing the bulky transporters.  
To do this, we developed the plasmid pBFVI depicted in Figure 5-8. In this 
vector, the cvaC and cvi genes were cloned downstream of ProTeOn+ in the pMS 
expression system with none of the corresponding secretion genes. We then transformed 
pBFVI into EcN and MC1061 for testing. MC1061 does not contain homologous 
secretion machinery to CvaA and CvaB so MccV should not be able to be secreted to the 
extracellular space. We proceeded to test the secretion efficacy using zone-of-inhibition 
assays on both minimal media (M9) and rich media (LB). On each test we included 
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unmodified EcN as a negative control to compare its native antimicrobial activity. The 
results of these halo tests are shown in Figure 5-9.  
From these results, we see that EcN has dramatic activity in minimal media 
without additional engineering due to its native antimicrobial activity. However, on LB 
EcN has a much smaller halo which is consistent with the idea that AMPs are activated in 
Figure 5-8. Plasmid map of pBFVI 
Figure 5-9. Zone-of-Inhibition assay for MccV secretion through MccH47 export 
machinery. . EcN(pBFV1), EcN, and MC1061(pBFVI) colonies were spotted on (a) M9 and 
(b) LB agar plates seeded with DH5α. On M9 unmodified EcN gives a large halo that is 
absent on the rich LB plate. EcN containing pBFV1 developed a halo on both plates while 
MC1061 (pBFVI) shows no halo on either plate.  
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times of nutrient depletion to help endowed strains in competition for survival. On LB, 
EcN containing pBFVI elicits a significant halo while MC1061(pBFVI) doesn’t give rise 
to a halo in either media. This leads us to believe that MccV is being efficiently exported 
from EcN, likely through the MccH47 secretion genes, mchE and mchF, although this has 
not been explicitly confirmed.  
5.5 Conclusions 
In this work we describe the development of a modular secretion tool that enables 
the production of multiple AMPs in parallel. The development of pMPES has led to a 
tool that could improve engineered probiotic treatments enabling them to be broader 
spectrum and/or exhibit increased potency against their desired target.  
The iterative development of pMPES led to an optimized construct, pMPES 3.0 
that exhibits dramatic increases in peptide secretion capacity. Through this work, we have 
refined the MccV operon solidifying the understanding of what genes are required for 
MccV production and secretion allowing for further optimization and utility studies. 
Since most peptides typically have a dedicated transport mechanism, this tool overcomes 
challenges with cloning and producing the secretion machinery required for each desired 
protein. Further, we demonstrate that EcN is capable of exporting MccV without the 
addition of the transport genes, presumably being released by the chromosomal MccH47 
pathway. One can envision tacking MccH47 compatible peptides to biosynthetic gene 
clusters for peptides such as MccJ25 and Mcc7 that require their dedicated pathways for 
an added antimicrobial effect with little cellular burden.  
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5.6 Materials and Methods 
5.6.1 Development and testing of pMPES 1.0 
See reference for detailed protocol: 
Geldart, K., Forkus, B., McChesney, E., McCue, M., & Kaznessis, Y. N. (2016). pMPES: 
A Modular Peptide Expression System for the Delivery of Antimicrobial Peptides to the 
Site of Gastrointestinal Infections Using Probiotics. Pharmaceuticals, 9(4), 60. 
5.6.2 Construction of pMPES 3.0 
IDT synthesized a gene fragment containing the sequence for cvaC and cvi which was 
inserted into the pMS expression vector using HIFI assembly making pBFV1. cvaC and 
cvaB were PCR amplified from pHK22 and inserted downstream of the terminator in 
pBFVI. 
5.6.3 Kinetic Supernatant Inhibition Assays of pMPES 1.0 and pMPES 3.0 
pMPES 1.0 and pMPES 3.0 producing MccV were transformed into the E. coli host 
strain, MC1061, and grown for 16hrs in LB. The supernatant of each culture was 
collected by transferring 1.5ml of the overnight culture to a microcentrifuge tube and 
centrifuging for 3min at 2.5rcf. The supernatant was sterile filtered using a .22µm filter. 
The supernatant was two-fold serially diluted in spent media from unmodified MC1061. 
DH5α (OD~0.01) was transferred to a 96-well plate and treated with each supernatant 
dilution, bringing the total volume to 300µl/well. The 96-well plate was transferred to a 
Biotek Synergy H1 plate reader and the plate was maintained at 37C in double-orbital 
mode. The OD600 was measured at 15 min intervals for 20hrs. Each supernatant 
treatment was run in triplicate and the error bars represent the standard error.  
5.6.4 Time to Rise (TTR) Method 
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To semi-quantify the amount of MccV in the supernatant, the TTR method was 
developed. From kinetic supernatant inhibition assays, the average growth curves were 
generated for each supernatant treatment by averaging the OD600 reading of each 
replicate at each time point. We set a cut-off at OD~0.2 and measured the time it took for 
the untreated growth curve to reach this value. We considered the ‘MIC’ to be the lowest 
supernatant concentration that significantly increased the TTR compared to the control. 
Bacteriocin units (BUs) are defined as the reciprocal of the lowest dilution that extended 
the TTR.  
5.6.5 Zone-of-Inhibition assays 
LB or M9 agar was inoculated with 10-100µl DH5α and plates were poured and allowed 
to harden. A colony of the strain of interest was spotted on top of the agar plate and 
incubated overnight allowing a zone of inhibition to form where the peptide diffused and 
inhibited the seed cultures growth.   
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Chapter 6 Conclusions and Future Perspectives 
 
Antibiotic resistance is a major public health concern. There is mounting global 
pressure to address the issue by reducing the use of antibiotics and incentivizing the 
development of next-generation therapies. In this thesis, we discuss the potential of 
engineered probiotics as an antibiotic alternative for pathogen-reduction in the clinical 
and agricultural sectors. 
AMPs are a largely untapped reservoir of antibiotic activity that hold promise in 
the fight against resistant organisms. AMPs have now been identified that display diverse 
structures, functions, and mechanisms of action. With the expansion of biotechnological 
tools in protein engineering, high-throughput cloning, and next-generation sequencing, 
more AMPs may soon be identified or developed with even better characteristics in 
aspects such as stability and activity. However, the practical use of AMPs has been 
limited largely due to delivery and synthesis challenges. In this work, we lay a foundation 
for using engineered probiotics to overcome these inherent limitations, making otherwise 
undeliverable peptides a viable treatment option. 
This thesis focuses on using synthetic biology approaches to systematically 
improve, understand, and engineer biosynthetic gene networks. Borne from this 
methodology were ProTeOn+ and pMPES, two novel synthetic biology tools that can aid 
in the development of future engineered organisms. 
ProTeOn+ is a well-characterized and robust promoter system which enables high 
constitutive expression of proteins from E. coli (Chapter 2). ProTeOn+ has been 
characterized using stochastic simulations and experimental assays demonstrating 
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predictable and well-defined behavior.  This promoter shows comparable expression 
capabilities to the fully induced T7 promoter system that is routinely used for protein 
production. Although in this work, we highlight the use of ProTeOn+ for the expression 
of AMPs it has many desirable qualities that could be used in other expression contexts, 
specifically applications where external induction is not desirable. 
pMPES and its derivatives (Chapter 5) demonstrate a method for heterologous 
secretion of peptides through the native MccV export pathway. We focus on the utility of 
pMPES for the secretion of bacteriocins in the aim of developing broader-spectrum 
probiotics or enhancing their antagonistic effect. In next steps, it is suggested that this 
system be explored as a general peptide export system. With a limited number of 
methods available for efficient protein secretion from E. coli, the ability to secrete 
proteins other than AMPs would greatly increase the value and utility of this tool in the 
context of synthetic biology. As a starting point, it is suggested to study the ability of 
smaller proteins with an inherent capacity to refold, such as affibodies, for release 
through this pathway by tagging with the Vsp leader sequence.  
This thesis focuses on engineering E. coli Nissle 1917 (EcN), a probiotic that has 
been studied for decades for its role in gastrointestinal health. We describe the use of EcN 
as a delivery vehicle for AMPs that target enteric pathogens, focusing on gram-negative 
bacteria as they remain one of the most challenging antibiotic-resistant subsets. In this 
methodology, we have developed EcN(J25) for control of Salmonella in poultry and 
EcN(C7) for decolonization of ST131 E. coli in the intestinal tract of human carriers. The 
work described in this thesis was highly translational where professional clinical and 
veterinary oversight was incorporated in the fundamental design stages to shape the 
 
 
91 
 
systems for their intended applications through strong collaborations with the VA 
Medical Center and Veterinary Science departments. 
In light of the recent regulations on antibiotic use in food-producing animals, 
engineered probiotics may have a promising future in this sector as a feed additive. The 
cornerstone of this thesis is our demonstration of the first in vivo success of AMP-
producing probiotics (Chapter 3). Treatment with our EcN(J25) system was capable of 
reducing Salmonella carriage by 97% in pre-harvest turkey poults 14-days post-
treatment. Bioinformatic analysis demonstrated this treatment elicited no negative 
impacts on the microbiota of the treated birds which is critical in their development. 
Although promising, further studies are suggested to optimize the use of 
engineered probiotics in animal feed applications. In the study presented, EcN(J25) was 
administered through a single oral gavage, three days following hatch; however, 
exploring alternative dosing regimens and administration methods could lead to a more 
effective treatment strategy. Co-localization studies are encouraged for currently it is not 
clear if EcN and Salmonella colonize the same part of the intestinal tract and what role 
their proximity plays. However, using a delivery strain that colocalizes with the target 
pathogen potentially could increase the treatment efficacy by limiting diffusion barriers 
and peptide degradation.  
In the younger project involving collaboration with colleagues at the VA Medical 
Center, we have developed an engineered probiotic EcN(C7) for the reduction of ST131 
carriage in the intestinal tract of infected individuals. The in vitro studies we have 
performed with EcN(C7) show this probiotic exhibits the strongest inhibitory effect of 
any probiotic/pathogen combination built previously in our lab. With the end-goal of 
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using this engineered probiotic in the clinic, we chose to explore the resistant 
subpopulation of the ST131 isolate, JJ1886, to unveil the mechanism of resistance. We 
have preliminary data suggesting that the YejF transporter on resistant cells is down-
regulated, blocking Mcc7 entry into the intracellular space.  
Looking forward, mouse trials are underway to determine the efficacy of EcN(C7) 
at JJ1886 reduction in vivo. Since the YejF transporter is known to play a role in the 
virulence of Salmonella and Brucella, it would be interesting to study the Mcc7-resistant 
isolates of JJ1886 and to quantify this subset’s colonization efficacy compared to the 
parental strains. Since YejF contributes to cell resistance to numerous AMPs, there may 
also be potential for combination therapies using AMPs to eliminate the Mcc7-resistant 
population.  
With the continual emergence of antibiotic-resistant bacteria and the challenges 
they present to health care, engineered probiotics are a potential method to harness the 
antibiotic activity of AMPs to expand our treatment options. This thesis helps build the 
foundation for the further growth of this field by highlighting some of the current 
successes, capabilities, and potential avenues for application of engineered probiotics. 
The modular nature of these systems enables tunable peptide expression and different 
pathogen/probiotic/peptide combinations can be readily developed to treat a variety of 
infections. Work must continue to evaluate the safety, efficacy, and optimization of 
engineered probiotics before they can gain widespread use. However, with the bleak 
outlook of a ‘post-antibiotic’ future upon us, engineered probiotics hold promise in the 
fight against microbial resistance and could re-open the medicine cabinet for future 
clinicians and patients.  
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Chapter 8 Appendix 
Appendix A: ProTeOn+: A Synthetic Hybrid Promoter for the Delivery of 
Antimicrobial Peptides 
 
  
 
Figure 8-1 ProTeOn+ and ProTeOn AND-Gate Comparisons.  The fluorescence of 
ProTeOn+ and the ProTeOn-AND gate were tested under varying experimental conditions 
and are represented as a function of cell density. A0-A5 are different inductions 
concentrations of the AND-Gate. A0: 0mM IPTG, 0ng/ml aTc, A1: 1mM  IPTG, 100ng/ml 
aTc, A2: 0.5 mM IPTG, 100ng/ml aTc, A3: 1mM IPTG, 0ng/ml aTc, A4: 1mM IPTG, 
0ng/ml aTc, A5: 0mM IPTG, 0ng/ml aTc. ProTeOn+: ProTeOn+ with no inducers. 
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ProTeOn+ Stochastic Kinetic Simulations 
The model presented in this work is adapted from the previous model developed 
by Volzing et al to describe the behavior of the ProTeOn AND-gate. The molecular level 
events that govern the GFP-expression profiles are displayed in the bimolecular reaction 
network displayed in Table 2-1 of the main text. The species abbreviations used in the 
reaction network are displayed in  
All reactions were modeled as occurring in a well-mixed volume of 10-1 2ml to 
represent the size of typical E. coli cells (9). Cellular division times were simulated 
according to experimentally obtained division rates upon induction with the each 
respective aTc concentrations as shown in Table 8-2. Each cell was assumed to initially 
contain 15-20 promoter and tetO binding sites based on the ColE1 plasmid copy number, 
450-550 available ribosomes for translation, and 150-300 RNA polymerase per cell. The 
initial conditions are shown in  
 
 
Table 8-1. Species Abbreviation in Bimolecular Reaction Network  
 
Table 8-2. aTc Induction concentrations used in silico and in vivo 
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Figure 8-2 Comparison of ProTeOn+ and P2 promoters.  Using the kinetic spectrophometric 
method described in Chapter 2, fluorescence and OD readings were measured from MC1061 
cells expressing GFP from the P2 and ProTeOn+ promoters. 
Table 8-3. Initial Conditions Used in Stochastic Kinetic Simulations 
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Figure 8-4. Plasmid maps of pBFG4, pBFG5, and pBFG6 
 
Figure 8-3. Plasmid map of pBFmut3.  The ProTeOn and GFPmut3 genes were synthesized by 
GENEART. They were cloned into a pMS expression vector containing a ColE1 origin of 
replication and Spectinomycin selection marker. 
Figure 8-5. Plasmid maps of constructs used to produce GFP under the control of ProTeOn+, T7, 
and OXB20. 
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Appendix B: Antimicrobial Probiotics Reduce Salmonella enterica in 
Turkey Gastrointestinal Tracts 
 
 
Figure 8-7. Trajectories of individual bird SE counts. The charts show the SE counts in 
the ceca for each individual bird at each collection point. The top row shows data 
collected for Trial 1 and the bottom shows the same data for Trial 2.   
Figure 8-6. Plasmid map of PBF25. pMS expression vector containing a ColE1 origin of 
replication and Spectinomycin selection marker. mcjABCD was cloned from PJP3 between 
EcorI and SacI restriction sites via standard molecular cloning procedures to create pBF25.  
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Figure 8-9. Trajectories of individual bird Nissle counts. The charts show the Nissle 
counts in the ceca for each individual bird at each collection point. The top row shows 
data collected for Trial 1 and the bottom shows the same data for Trial 2. Error bars 
represent standard error. Samples below limit of detection are plotted on the x-axis. 
Figure 8-8. Bird weight profiles of in vivo trials. The left column shows the average bird 
weights of the euthanized birds at each time point for each respective trial. The right column 
shows the bird weights for the individual birds euthanized at the final time point, 14 days 
post SE-challenge. The width of the lines and error bars correspond to the standard error 
and the color represents the treatment group. The groups show no statistical difference in 
average bird weight across all time points. 
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Figure 8-10. SE-susceptibility to MccJ25 following GI passage. 12 SE isolates were collected 
from birds treated with (a) SE+ PBS and (b) EcN(J25) + SE after passage to the ceca on day 14 
post challenge to determine if any resistance was developed to MccJ25. The isolates were 
challenged with 0 and 20% by volume of EcN(J25) supernatant that was collected after 20hrs of 
growth. Kinetic growth curves were generated using the supernatant activity assay described in 
the materials and methods.  Same color refers to the same isolate, solid line is growth in absence 
of MccJ25 and dotted line is growth in the presence of MccJ25. No resistance is observed in any 
of the 12 isolates in either group as clear growth inhibition is observed across all isolates in both 
treatment groups. 
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Figure 8-11. Microbiome diversity at final time point  (a) Alpha diversity of all treatment 
groups in Trial 2. (b) Heat map comparing the frequencies of major bacterial species for 
each bird necropsied at the final time point for all treatment groups in (left) Trial 1 and 
(right) Trial 2. Each column represents an individual bird. 
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Figure 8-12. Q-Q plot for comparing raw and log10 transformed data for normality. A 
Q-Q plot enables the determination of whether a distribution assumption is valid. The 
SE counts from day 14 in both Trial 1 (top) and 2 (bottom) were tested for normality 
using the raw (left) and transformed (right) values. The transformed data appears to yield 
a better approximation. 
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Appendix C: Engineered Probiotics to Target Multidrug Resistant E.coli 
 
 
 
Table 8-4. Sequences of promoters, Pmcja, Pcvi, and Pmcc.  The uppercase regions 
represent the homology regions used for the HIFI assembly reaction 
Figure 8-13. Zone-of-Inhibition screens of MccV and MccJ25 against JJ1901 and MVAST020. 
MC1061 cells producing pBF25 and pMPES3 were screened against JJ1901(left) and 
MVAST020(right) in duplicate.  
